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ABBREVIATIONS 
7TM seven transmembrane 
A68930 (1R,3S)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1H-isochromene-
5,6-diol 
AB assay buffer 
ATP adenosine triphosphate 
BacMam a recombinant baculovirus for delivering genes of interest into 
mammalian cells 
Bacmid baculovirus shuttle vector 
Bmax maximal number of receptor binding sites 
BSA bovine serum albumin 
BV baculovirus 
cAMP 3',5'-cyclic adenosine monophosphate 
D1-D5 dopamine receptor subtypes 
DA dopamine 
DPBS  Dulbecco’s Phosphate-Buffered Saline 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO dimethyl sulfoxide 
DTT dithiothreitol 
EC50 concentration of the sample that produces 50% of the maximal 
possible effect 
EDTA ethylendiaminetetraacetic acid 
FA fluorescence anisotropy 
FRET Förster/fluorescence resonance energy transfer 
GDP guanine diphosphate 
GTP guanine triphosphate 
GPCR G protein-coupled receptor 
HB homogenization buffer 
HEK293 human embryonic kidney cells 293 
IB incubation buffer 
IC50 molar concentration of an unlabeled ligand that inhibits binding of 
a labeled ligand by 50% 
ivp infectious viral particles 
KD equilibrium dissociation constant of a ligand determined directly in 
a binding assay using a labeled ligand 
Ki inhibition constant, refers to an equilibrium dissociation constant 
of an unlabeled ligand measured in competition with a labeled 
ligand  
koff dissociation rate constant 
kon association rate constant 
L-DOPA  L-3,4-dihydroxyphenylalanine 
LE300 7-methyl-6,7,8,9,14,15-hexahydro-5H-benz-[d]indolo[2,3-
g]azecine 
 9  
MNPA 2-methoxy-10,11-dihydroxy-N-propylnorapomorphine 













TFI total fluorescence intensity 
TRIS 2-amino-2-(hydroxymethyl)-1,3-propanediol 
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INTRODUCTION 
Biopolymers like polysaccharides, nucleic acids and proteins are essential for 
all living organisms. Besides water, proteins are the most abundant type of 
molecules in the human body. Proteins are also the most versatile of all bio-
molecules, performing many functions required for life. Some proteins have 
catalytic activity and function as enzymes, others serve as structural elements, 
signal receptors, or transporters that carry specific substances into or out of the 
cells. This thesis focuses on the receptor proteins, specifically to G protein-
coupled receptors that are located in the cell’s plasma membrane. These pro-
teins are responsible for detecting various chemical of physical signals outside 
the cell by binding specific chemical compounds, called ligands. Ligand 
binding to a receptor can initiate a conformational change in the structure of the 
protein, which in turn leads to a chain of biochemical events inside the cell.  
Dopamine receptors, belonging to the family of G protein-coupled receptors, 
mediate several functions in the central nervous system, including control of 
locomotion, cognition, emotion, positive reinforcement, food intake and endo-
crine regulation. These receptors also have an important role in the periphery, 
where they modulate cardiovascular function, catecholamine release, hormone 
secretion, vascular tone, renal function and gastrointestinal motility. Abnormal 
dopaminergic signaling can lead to several neurological and psychiatric dis-
orders and therefore these receptors are relevant targets in the pharmaceutical 
industry. Drugs that bind to dopamine receptors have been clinically used in the 
management of several diseases, such as schizophrenia, Parkinson’s disease, bi-
polar disorder, Huntington’s disease, attention deficit hyperactivity disorder and 
Tourette’s syndrome. 
Dopamine receptors have been in the center of G protein-coupled receptor 
research and numerous advancements have been made in understanding the 
structural, biochemical and functional properties of these proteins. However, 
much remains unclear and therefore developing methods that could help to gain 
more information about dopaminergic signaling and facilitate the development 
of better drugs is necessary. Thus, the aim of this study was to implement novel 
assay systems to characterize ligand binding to different subtypes of dopamine 
receptors. Experiments were carried out with several different receptors, in-
cluding native receptors (tissue homogenates) and various recombinant protein 
expression systems (mammalian and insect cells, budded baculovirus particles) 
by using several methods to characterize receptor-ligand interactions with the 
emphasis on fluorescence-based methods. 
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1. LITERATURE REVIEW 
1.1. G protein-coupled receptors 
The ability of cells to receive and act on signals is fundamental to life for higher 
organisms. Usually, the signal represents information that is received by speci-
fic proteins and then converted into a cellular response. This process, where 
chemical or physical signal is transmitted through a cell as a series of molecular 
events, is called signal transduction. Proteins that are responsible for detecting 
these external signals are known as receptors, which have been broadly clas-
sified into six basic classes: transmembrane receptors that include G protein-
coupled receptors (GPCRs), receptor tyrosine kinases, receptor guanylyl cyc-
lases, gated ion channels, adhesion receptors and intracellular nuclear receptors 
(Nelson and Cox 2008). About 800 GPCRs have been identified in humans 
(Wacker et al. 2017). Approximately half of these mediate sensory functions, 
like olfaction (~400), taste (33), light perception (10) and pheromone signaling 
(5). The remaining ~350 GPCRs are binding natural ligands that range in size 
from small molecules to large proteins (Alexander et al. 2017).  
Several classification schemes have been proposed to categorize GPCRs, but 
according to IUPHAR/BPS Guide to PHARMACOLOGY most of the human 
GPCRs can be divided into five classes: Glutamate (class C), Rhodopsin (class 
A), Adhesion, Frizzled/Taste2 (class F) and Secretin (class B) (Alexander et al. 
2017). This is called the GRAFS classification system developed by the se-
quence similarities of GPCRs (Schiöth and Fredriksson 2005), in which 
rhodopsin constitutes the largest family that is further divided into four main 
groups (α, β, γ, δ) with 13 sub-branches. In general, the α-group includes 
GPCRs that bind amines and some peptides, the β-group includes only peptide 
binding GPCRs, the γ-group contains peptide, neuropeptide and opioid binding 
GPCRs and the δ-group includes a large group of olfactory receptors, purin 
receptors and glycoprotein receptors (Schiöth and Fredriksson 2005). 
All GPCRs share common structural features, like an extracellular N-termi-
nus, an intracellular C-terminus and seven transmembrane (7TM) α-helices con-
nected by three intracellular and three extracellular loops (Palczewski et al. 
2000). The term “7TM receptor” is often used as a synonym of GPCR to em-
phasize the existence of seven hydrophobic transmembrane domains. These 
transmembrane helices share the greatest homology between different GPCRs, 
while the most variability can be seen in N-terminus, followed by C-terminus and 
intracellular loop between transmembrane helices five and six. For example, the 
N-terminus is relatively short in monoamine and peptide receptors (10–50 
amino acids) and much longer (350 – 600 amino acids) in glycoprotein hor-
mone receptors and the glutamate family receptors (Kobilka 2007). While the 
extracellular domain is the least conserved, GPCRs have great homology at the 
cytoplasmic ends of the transmembrane helices, giving evidence of a conserved 
mechanism on activation and signal transduction (Mirzadegan et al. 2003).  
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For a particular cell the first step of signal transduction is a ligand interacting 
with a receptor. Precise molecular complementarity between the ligand and the 
receptor secures remarkable specificity of the signal transduction. The structure 
and function of GPCRs is similar in contrast to the structural diversity of the 
natural ligands, therefore it is only befitting that there are differences in sites 
and modes of ligand binding. Ligand binding domains have been determined for 
numerous GPCRs – many small ligands bind in the transmembrane region, but 
peptide hormones and proteins often bind to the N-terminus and extracellular 
loops (Ji et al. 1998). However, the location of the binding site does not only 
depend on the size of the ligand. For example, glycoprotein hormones, gluta-
mate and Ca2+ are recognized by the large extracellular domain of the cor-
responding receptor (Pin et al. 2003).  
Irrespective of the exact location of binding site the overall purpose of ligand 
binding remains the same. Upon ligand binding the GPCR undergoes a confor-
mational change leading to subsequent activation of heterotrimeric G proteins 
(Rosenbaum et al. 2009). These guanine nucleotide-binding proteins (shortly G 
proteins) compose of three subunits: α, β and γ. In the inactive state guanine 
diphosphate (GDP) is bound to the α-subunit of a G protein. Conformational 
changes in the receptor catalyze the dissociation of GDP that is followed by the 
association of guanine triphosphate (GTP) with the α-subunit. Binding of GTP 
causes a dissociation of the G protein subunits from each other and from the 
receptor yielding a monomeric α-subunit and a βγ dimer. Both of these can now 
regulate the activity of the appropriate effectors, such as second-messenger-
generating enzymes or specific ion channels (Gainetdinov et al. 2004). Hydro-
lysis of GTP to GDP and inorganic phosphate initiates the deactivation of G 
proteins, thus allowing reassociation of the subunits. GPCRs vary in their 
specificity to activate distinct G protein types. Based on the sequence homology 
of their α-subunit (Gilman 1987) GPCRs can be divided into four main families: 
Gi/o, Gs/olf, Gq/11, G12/13 (Simon et al. 1991). Gs/olf and Gi/o transduce the signal via 
membrane-associated enzyme adenylate cyclase, either by activating (Gs/olf) or 
inhibiting (Gi/o) the enzyme. Hence, these G proteins influence the intracellular 
3',5'-cyclic adenosine monophosphate (cAMP) levels. Gq/11 subunit activates 
phospholipase C, which in turn hydrolyzes phosphatidylinositol-4,5-bis-
phosphate into two second messengers – diacyl glycerol and inositol 1,4,5-
trisphosphate. This causes the activation of protein kinase C and the intra-
cellular Ca2+ mobilization. G12/13 regulate cell processes through the use of gua-
nine nucleotide exchange factors and therefore control the cell cytoskeleton 
remodeling and cell migration (Siehler 2007). Despite extensive studies, the 
GPCR and G protein coupling profile remains incomplete. Some GPCRs can 
only signal via single type of G protein, whereas many receptors can couple to a 
broader range of G protein families (Siehler 2007, Miyano et al. 2014).  
This signaling cascade cannot be induced by all the ligands that bind to 
GPCRs. The ligands binding to the GPCR’s active site (also called the ortho-
steric site) can be categorized based on their effect on the receptor function. A 
ligand that alters the receptor state resulting in a biological response upon 
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binding is called an agonist. Classical agonist increases receptor activity, while 
inverse agonist reduces it. Agonists are further divided as partial and full ago-
nists, depending on the degree of effect produced. The effect of an agonist can 
be reduced by an antagonist, which upon binding does not result in cellular 
response. In addition to orthosteric ligands there are also allosteric ligands that 
increase or decrease the action of orthosteric ligands by binding to distinct 
allosteric sites on the receptor molecules (Neubig et al. 2003). 
While GPCR signaling is essential, overstimulation can be deleterious, re-
sulting in cellular toxicity or uncontrolled cellular growth. Therefore, a number 
of mechanisms exist for limiting GPCR signaling (Rajagopal and Shenoy 2018). 
GPCRs respond to agonists in a dose-dependent manner so that the concentra-
tion of the agonist is the primary control point for GPCR signaling (Gainetdinov 
et al. 2004). Hence, the signal attenuation includes removal of agonists from the 
extracellular fluid by dilution, uptake by transporters or enzymatic degradation 
(Böhm et al. 1997). However, one important feature of G protein signaling sys-
tem is that it exhibits a memory of prior activation or signaling tone (Hausdorff 
et al. 1990). Thus, high activation of GPCR leads to a reduced ability to be 
stimulated in the future (desensitization), while low activation leads to an in-
creased stimulation (sensitization). A good example is the “light receptor” rho-
dopsin, which adjusts to both dark and light within moments. This regulation 
can be achieved at the level of receptor itself in two main ways: by adjusting the 
signaling efficacy of receptors and by controlling the number of GPCRs present 
in the cell plasma membrane (Gainetdinov et al. 2004). Short-term desensiti-
zation occurs over minutes and is primary associated with phosphorylation of 
the agonist-activated receptors by G-protein receptor kinases followed by 
binding of β-arrestins that block further G protein-mediated signaling (Raja-
gopal and Shenoy 2018). Longer-term desensitization, referred to as downregu-
lation, occurs over hours to days and involves agonist-induced receptor endo-
cytosis, which can lead to either (i) dephosphorylation, resensitization and rec-
ycling to the membrane, (ii) targeting to lysosomes and degradation, (iii) 
activation of additional intracellular signaling pathways (Reiter and Lefkowitz 
2006, Rajagopal and Shenoy 2018). Majority of GPCRs use clathrin-mediated 
internalization pathway that requires prior G protein receptor kinase mediated 
phosphorylation and subsequent β-arrestin recruitment (Shenoy and Lefkowitz 
2003). Downregulation may even lead to decreased receptor mRNA levels that 
alters the rate of GPCR synthesis (Rajagopal and Shenoy 2018). 
Individual GPCRs have unique combinations of signal-transduction activi-
ties involving G proteins as well as G protein-independent signaling pathways 
(Rosenbaum et al. 2009). It has been even proposed that the term GPCR should 
be abandoned in favor of 7TM receptors, because these proteins also signal 
without coupling to G proteins (Kobilka 2007). Nowadays it has become in-
creasingly evident that the functions of abovementioned G protein receptor 
kinases and β-arrestins are not restricted to only desensitization and interna-
lization. These two protein families also mediate the G protein-independent 
signaling of GPCRs (Reiter and Lefkowitz 2006). The list of described β-
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arrestin-dependent signaling pathways has been growing rapidly and for 
example mitogen-activated protein kinases (JNK3, ERK1/2, p38 MAPK) can be 
activated via these proteins (Shenoy and Lefkowitz 2003). Interestingly, it has 
been demonstrated that some agonists can produce activation of some but not 
all available pathways. These are referred to as “biased” agonists, because they 
select which signaling pathways become activated upon binding to the receptor. 
Biased agonists have been shown to variously activate different G proteins and 
β-arrestins and have varying susceptibility to phosphorylation, desensitization 
and internalization (Kenakin 2009).  
GPCRs have fundamental roles in virtually all physiological functions (Rei-
ter and Lefkowitz 2006) and are expressed throughout the human body (Wacker 
et al. 2017). Therefore, problems with GPCR mediated signal transduction can 
also cause various disorders. For example, these receptors have been implicated 
in many common diseases including allergies, depression, blindness, diabetes 
and various cardiovascular defects (Nelson and Cox 2008). As of November 
2017, 134 GPCRs are targets for drugs approved in the United States or Euro-
pean Union (Sriram and Insel 2017). Particularly prominent therapeutics in-
volving GPCRs include opioid analgesics, antihistamines, anticholinergics, anti-
psychotics, antimigraine drugs, antihypertensives and asthma drugs (Wacker et 
al. 2017). Around 700 approved drugs target GPCRs, implying that approxima-
tely 35% of approved drugs mediate their effects by modulating GPCR sig-
naling pathways (Sriram and Insel 2018). This illustrates the importance of 
GPCR research and even though many aspects of signal transduction are al-
ready known, much remains unclear. Therefore, development of novel, sensitive 
analytical methods or implementation of existing techniques in an innovative 
way is of utmost importance.  
 
 
1.1.1. Dopamine receptors 
Catecholamines are natural GPCR ligands that contain a benzene ring with two 
adjacent hydroxyl groups (also called a catechol group) as well as an ethylene-
amine side chain that may have additional N-substituents (Brady et al. 2011). 
Predominant catecholamine neurotransmitters in the brain are dopamine (DA), 
norepinephrine and epinephrine. Norepinephrine was the first of them to be re-
cognized as a central neurotransmitter in 1954 by M. Vogt (Vogt 1954). At that 
time, DA was only thought to be a precursor of norepinephrine. In fact, dopa-
mine is an intermediate in the biosynthesis of both norepinephrine and epi-
nephrine. DA itself is synthesized from an amino acid tyrosine by the removal 
of a hydroxyl group to produce levodopa (L-DOPA). Decarboxylation of L-
DOPA produces dopamine, which can then be converted to norepinephrine or 
further into epinephrine (Brady et al. 2011). 
It was soon discovered by A. Carlsson and colleagues that DA can also 
function as an independent neurotransmitter (Carlsson et al. 1957). Interest in 
dopamine increased as it was realized that DA had an important role in certain 
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neurological and psychiatric disorders, like Parkinson’s disease, schizophrenia, 
Tourette’s syndrome, bipolar disorder, depression, hyperprolactinemia and 
attention deficit hyperactivity disorder (Missale et al. 1998, Strange and Neve 
2013, Beaulieu et al. 2015). Dopamine has also been found to be essential in the 
brain reward system, hence it is also associated with drug dependence and 
addiction (Marsden 2006).  
The first evidence that dopamine elicits its effect by binding to a cell-surface 
receptor came from the experiments showing the stimulation of adenylate 
cyclase by DA (Kebabian et al. 1972). The receptors described by Kebabian 
and colleagues are nowadays known and classified as dopamine D1-like recep-
tors. Soon a receptor that could bind dopamine and haloperidol was identified 
and called “neuroleptic/dopamine receptor” (Seeman et al. 1976). The paper 
also demonstrated that clinically effective antipsychotic drugs block binding of 
haloperidol. This receptor was later named as dopamine D2 receptor (Kebabian 
and Calne 1979), which is a key target for several antipsychotic drugs. Keba-
bian and Calne also proposed that the two dopamine receptors that had been 
discovered belong to a separate class and hypothesized the existence of additio-
nal dopamine receptor subtypes (Kebabian and Calne 1979). Indeed, more 
dopamine receptor subtypes were discovered after the advancement in mole-
cular biology enabled gene cloning of the receptors (Marsden 2006). Nowadays 
it is known that the effects of dopamine are mediated through five G protein-
coupled receptors: D1, D2, D3, D4, D5 (Gainetdinov et al. 2017). These subtypes 
are further divided into two families, D1-like and D2-like receptors, based on 
their sequence homology, pharmacological profile and by the ability to couple 
either with Gs/olf or Gi/o proteins. D1-like receptors include D1 and D5 subtypes 
and the genes of these receptors do not contain introns in their amino acid 
coding regions (Missale et al. 1998). These two receptors activate the enzyme 
adenylate cyclase that catalyzes the formation of cAMP from ATP. Hence, 
activation of these receptors stimulates cAMP formation (Brady et al. 2011). 
Increase in the second messenger cAMP concentration may lead to the acti-
vation of protein kinase A (Walsh et al. 1968), modulation of cyclic nucleotide-
gated ion channels (Fesenko et al. 1985, Kaupp and Seifert 2002) and exchange 
proteins activated by cAMP (De Rooij et al. 2000), to name a few. Contrary, 
D2-like receptors (D2, D3, D4) inhibit the enzyme adenylate cyclase and the 
formation of cAMP by coupling to Gi/o protein. These subtypes also contain 
introns and alternative splicing may result in different isoforms of receptors, 
such as the short (D2S) and long (D2L) variants of D2 receptor (Gainetdinov et al. 
2017). D2-like receptors are expressed both postsynaptically and presynaptically 
while D1-like receptors are exclusively found on postsynaptic cells (Beaulieu 
and Gainetdinov 2011). 
In addition to previously mentioned differences, D1-like and D2-like recep-
tors share some structural dissimilarities, whereas members of the same family 
have considerable homology. The highest degree of amino acid sequence simi-
larity is in the transmembrane domains: DA receptors share 31% sequence 
identity in that region and the similarity increases between members of the same 
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family (75% for D1-like and 52% for D2-like receptors) (Civelli 1993). The D1-
like receptors have a short intracellular loop 3 that is common for receptors 
coupling with Gs/olf, while the D2-like receptors possess a long third intracellular 
loop as in many adenylate cyclase inhibiting GPCRs. Additionally, D1-like 
receptors possess about seven times longer carboxyl terminus that is rich in 
serine and threonine residues and contains a cysteine residue near the beginning 
of the C-terminus. In D2-like receptors, the cysteine residue is located in the end 
of carboxyl terminus (Gingrich and Caron 1993). This cysteine is conserved in 
all GPCRs and has been shown to be palmitoylated for anchoring the cyto-
plasmic tail to the membrane (Ovchinnikov et al. 1988, Ebersole et al. 2015). 
Additional conserved cysteine residues are in the extracellular loop 2 and 3, 
which are suggested to form a stabilizing intramolecular disulfide bridge in 
GPCRs (Dohlman et al. 1990). Compared to the carboxyl terminus, N-terminus 
has a similar number of amino acids in all dopamine receptor subtypes. N-
glycosylation sites are also located in the N-terminus, but the number of poten-
tial glycosylation sites varies among different subtypes (Missale et al. 1998).  
Dopamine receptor subtypes belonging to the same family have considerable 
homology in their structure, but still differ enough to have distinctive pharma-
cological profiles. For example, the main differences between D1 and D5 recep-
tors are in the amino acid sequences of third intracellular loop and carboxyl 
terminus, which are therefore the key structural features causing the functional 
differences of these two receptor subtypes. Also, there is some considerable 
variation in the extracellular loop 2 region, which is much shorter in D1 receptor 
(27 amino acids) than in D5 (41 amino acids) (Missale et al. 1998). Differences 
between D2-like receptors’ structures can now be precisely characterized due to 
the existence of crystal structures for all the subtypes. The crystal structure of 
D3 receptor (Chien et al. 2011) was reported seven years ago, while the struc-
tures for D4 (Wang et al. 2017) and D2 (Wang et al. 2018) have been obtained 
only recently and the structures of D1-like receptors have not been published. 
These three crystal structures all represent inactive receptor states, binding 
either inverse agonists or antagonists. Compared to the other D2-like receptors 
D2 displays substantial structural differences in extracellular loops 1 and 2 and 
in the extracellular regions of transmembrane helices V, VI and VII. These and 
some additional key characteristics further described in Wang et al. 2018 are 
responsible for the unique ligand binding mode of D2 receptor, where the ligand 
engages a deeper binding mode which has not been described for neither D3 nor 
D4 receptor. 
Dopamine receptors are widely expressed in the central nervous system, 
where they are involved in the control of locomotion, cognition, emotion, posi-
tive reinforcement, food intake and endocrine regulation. Dopamine also has an 
important role in the periphery, where it modulates cardiovascular function, 
catecholamine release, hormone secretion, vascular tone, renal function and 
gastrointestinal motility (Missale et al. 1998, Beaulieu and Gainetdinov 2011). 
The previously described model of dopamine receptor signaling via activation 
or inhibition of adenylate cyclase is too simplistic to explain the functional fle-
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xibility of these receptors. It is now known that dopamine receptors regulate 
multiple signaling pathways by interacting with various G proteins and by G 
protein-independent mechanisms, such as ion channels, receptor tyrosine kina-
ses and β-arrestins (Beaulieu et al. 2015). For example, there are indications 
that both D1 and D2 receptors can transactivate the brain-derived neurotrophic 
factor receptor in neurons (Swift et al. 2011), regulate calcium channels through 
a direct protein-protein interaction (Kisilevsky and Zamponi 2008, Kisilevsky et 
al. 2008) and interact with Na+-K+-ATPase (Hazelwood et al. 2008). It has also 
been demonstrated that dopamine D1-like receptors can regulate inositol 
trisphosphate-mediated signaling (Sahu et al. 2009, Medvedev et al. 2013) via 
coupling to Gq/11 proteins. D2-like receptors’ signaling is also largely mediated 
via βγ dimer of G protein leading to activation of phospholipase C and increase 
in cytoplasmic calcium concentration (Hernandez-Lopez et al. 2000), regulation 
of the activity of L- and N-type calcium channels (Yan et al. 1997, Hernandez-
Lopez et al. 2000) as well as G protein-coupled inwardly rectifying potassium 
channels (Kuzhikandathil et al. 1998). Additionally, there is increasing evi-
dence that G protein mediated signaling of dopamine receptors can even 
influence the phosphorylation and therefore functioning of ionotropic glutamate 
receptors (Beaulieu et al. 2015). D2 receptors are also able to signal via G 
protein-independent pathways by interacting with β-arrestins, leading to inacti-
vation of serine/threonine kinase Akt and activation on glycogen synthase 
kinase 3 (Beaulieu et al. 2004).  
Further complexity in signal transduction comes from the fact that GPCRs 
can exist in oligomeric forms. This is also the case for dopamine receptors, 
which can form homodimers between two identical receptors and heterodimers 
by interacting with other members of the same family or with structurally diver-
gent receptor families. These heterodimers can have different pharmacological, 
signaling and trafficking properties compared to the monomeric receptors 
(Angers et al. 2002). Members of dopamine receptor family are known to form 
following heterodimers: D1-D2, D1-D3, D2-D3, D2-D4 (Pou et al. 2012, Beaulieu 
et al. 2015). In some cases, existence of the dimers has been proved, but the 
biological function remains unclear and needs further investigation, whereas for 
some dimers the research has been more conclusive. For example, it is known 
that activation of D1-D2 complex has unique pharmacology that is distinct from 
of its single monomer, leading to the signaling via Gq/11 protein and successive 
release of Ca2+ from the internal store (Rashid et al. 2007). Also, there is in-
creasing evidence that glutamate N-methyl-D-aspartate receptor can interact 
with both dopamine D1 receptors (D1-NMDA dimer) and D2 receptors (D2-
GluN2B) (Beaulieu et al. 2015). These interactions seem to be physiologically 
relevant, because disruption of the D1-NMDA complex led to working memory 
impairment (Nai et al. 2010) and disruption of D2-GluN2B reduces cocaine-
stimulated locomotor activity (Liu et al. 2006). Furthermore, many studies have 
shown that adenosine receptors can form heterodimers with dopamine recep-
tors, resulting in D1-A1 and D2-A2A complexes (Ginés et al. 2000, Hillion et al. 
2002). In both dimers activation of adenosine receptor can antagonize the 
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cAMP responses because adenosine and dopamine exert opposing effects in the 
brain. The list of receptors, which could form dimers with dopamine receptors 
is not conclusive and several additional dopamine receptor heterodimers have 
been described in Beaulieu et al. 2015. Taken together, the complex biology of 
dopamine receptor-mediated signal transduction mechanisms might represent a 




1.1.1.1. Dopaminergic ligands 
Dopaminergic drugs may modulate different parts of the dopaminergic signal 
transduction. For example, they may affect the enzymes catalyzing the synthesis 
of dopamine or degradation of DA, influence the DA release or reuptake, or 
bind to the dopamine receptors. Herewith, we concentrate on the ligands of 
dopamine receptors that are often in the focus of drug development. Usually 
agonists of dopamine receptors are known to treat the symptoms of Parkinson’s 
disease, while the antagonists are used as antipsychotics in the treatment of 
schizophrenia. Depletion of DA in Parkinson’s disease is commonly relieved by 
administration of L-DOPA. Unfortunately, its long-term use causes motoric 
complications such as dyskinesia (Zhang et al. 2008). Dopaminergic system is 
also involved in drug reinforcement and addiction (Volkow et al. 2009). A wide 
variety of addictive substances directly or indirectly affect dopaminergic signal 
transduction. Therefore, therapeutic interventions aimed at restoring normal 
dopaminergic signaling in drug users are of utmost importance. Moreover, some 
drugs that are designed to target other GPCRs may also affect dopaminergic 
system and therefore cause addiction among other side effects. 
The most highly expressed dopamine receptor subtype is D1 receptor which 
also plays a crucial role in a variety of cognitive functions and is implicated in 
substance abuse disorders. Although the first D1-like selective antagonist 
SCH23390 was introduced more than three decades ago (Hyttel 1983), cli-
nically useful D1 ligands are rare. It is difficult to develop ligands that are 
specific for the D1 and not to the D5 receptor and all currently available ligands 
have similar affinity and potency to both D1-like receptors (Nichols 2010). D1-
like receptors have high affinity for the benzazepine antagonists (SCH23390, 
SCH39166, SKF83566) that are also selective for D1 and D5 receptors. Another 
high affinity D1 antagonist is LE300, which is structurally distinct from the 
benzazepines (Strange and Neve 2013).  
Previous research indicates that D1 agonists may be therapeutically useful in 
the treatment of Parkinson’s disease (Li and Zhou 2013) and may also improve 
cognition and working memory in schizophrenia and age-related cognitive 
decline (Nichols 2010). The first known D1-like agonist drug was apomorphine 
that can be easily synthesized from morphine. Interestingly, N-alkylation of 
apomorphine yields ligands with reduced affinity for D1-like receptors and 
improved affinity for D2-like receptors with N-propyl analog (NPA) having the 
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greatest selectivity. This observation seems to be a general property of dopa-
minergic ligands and has been referred to as the “propyl effect” (Nichols 2010). 
The discovery of a partial agonist SKF38393 was a breakthrough in DA re-
search, as the molecule was highly selective for D1-like receptors. Other benza-
zepine derivates (SKF81297, SKF38393) and dihydrexidine derivates (A86929, 
dihydrexidine, doxanthrine) are also D1-like receptors’ selective agonists 
(Strange and Neve 2013).  
D2-like receptor antagonists are divided into classical and atypical anti-
psychotics. The classical family includes phenothiazines (such as chlorproma-
zine), thioxanthenes (chlorprothixene), butyrophenones (haloperidol) and 
diphenylbutyl piperidines (pimozide) (Prante et al. 2010). These drugs are able 
to reduce the positive symptoms of schizophrenia but also have extrapyramidal 
side effects. In contrast, atypical drugs are able to influence positive and nega-
tive symptoms of schizophrenia and are less likely to produce side effects. 
Examples of these drugs include clozapine and olanzapine (Prante et al. 2010). 
Well-known D2-like receptors’ selective antagonists also include substituted 
benzamides (sulpiride, raclopride). Most of these antagonists have a similar 
affinity for all D2-like receptors. However, selective antagonists for different 
D2-like receptor subtypes have been developed. For example, L741626 is selec-
tive for D2, NGB2904 for D3 and L745870 for D4 receptors (Strange and Neve 
2013). Older D2-like receptors agonistic drugs, such as bromocriptine and 
cabergoline are not selective and affect several subtypes. Now, several subtype 
selective agonists have been developed for D2-like receptors, like sumanirole 
for D2 and A412997 for D4 receptors (Strange and Neve 2013). The maximal 
selectivity between different dopamine receptor subtypes has been seen for D4 
receptors’ ligands with more than a 1000-fold higher affinity compared to the 
affinity for other subtypes (Beaulieu and Gainetdinov 2011). 
A new promising direction for drug development is based on the functional 
selectivity. These biased ligands may be more efficacious drugs or have fewer 
side effects (Strange and Neve 2013). An interesting example of functional 
selectivity has been discovered with the D1-D2 heterodimer. An agonist 
SKF83959 activates the Gq/11 pathway leading to phospholipase C response 
without affecting Gs/olf-coupled D1 receptors (Rashid et al. 2007). Another 
agonist SKF81297 can activate both Gq/11 and Gs/olf pathway and a ligand 
SKF83822 activates only Gs/olf pathway leading to activation of adenylate 
cyclase. These results indicate that the pharmacology of dopaminergic ligands is 
complicated and needs further investigation. For that, novel methods that could 
provide new insight about receptor-ligand interactions are required. 
Some structures of the abovementioned ligands are presented in Figure 1.   




Figure 1. Examples of dopamine receptor ligands. These are the structures of the 
ligands that were used in the ligand binding experiments performed in this thesis. 
Stereochemistry is defined on structural formulas unless specified in name. 
 
 
1.2. Ligand binding assays 
The suggestion that chemical agents must be specifically bound to structures in-
herent to the living organisms before exerting an effect was first proposed by 
John Newport Langley in 1878 (Gesztelyi et al. 2012). At that time experiments 
were carried out on live animals or with animal tissues. For example, Langley 
studied the effect of pilocarpine (partial agonist of muscarinic acetylcholine re-
ceptors) on salivary secretion in the dog (Langley 1876). In these experiments 
he demonstrated that pilocarpine stimulated salivary production and atropine 
(antagonist) stopped it. Other similar tissue responses were used as a “signal” 
caused by certain chemical substances, like deceleration/acceleration of the 
heart rate, contraction of skeletal muscle etc. Experiments were also carried out 
with smaller organisms – Paul Ehrlich performed bacteriological investigations 
which lead him to believe that the cell protoplasm was supposed to have certain 
side-chains that were able to bind chemically the toxins produced by the 
bacteria (Maehle 2009). He later replaced the term “side-chain” with the term 
“receptor”.  
For a long time, the in vivo approach was the only method for characterizing 
and studying receptors. More knowledge about the interaction between a 
receptor and its ligands could be obtained from direct ligand binding assays, 
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which only became possible after introduction of radioligands in 1970s (Paton 
and Rang 1965, Lefkowitz et al. 1970). Receptor-ligand binding assays were 
among the earliest in vitro methods used to study receptor function and they 
continue to be an important tool in fundamental GPCR biology as well as in 
pharmacological industry for development and characterization of novel drug 
candidates (Flanagan 2016). In most cases, these assays rely on the use of 
labeled (radioisotope or fluorescent dye) ligands and therefore our focus will be 
on the corresponding methods. Ligand binding assay can be used to measure the 
concentration and localization of receptors in tissues or cells, to determine the 
affinity of a labeled ligand for the receptor of interest and to estimate kinetic 
parameters of ligand binding reaction, like association and dissociation rates 
(Zhang and Xie 2012). Additionally, binding parameters of unlabeled ligands 
could be characterized in competition binding experiments with a labeled 
ligand. However, ligand binding assay generally cannot be used to distinguish 
agonists from antagonists or inverse agonist, because direct interaction between 
a ligand and a receptor is measured instead of a physiological response 
(Flanagan 2016).  
Fundamentally, receptor binding experiments can be divided into three basic 
types: kinetic experiments, where ligand binding is measured in time to deter-
mine association (kon) and dissociation (koff) rate constants; saturation binding 
experiments, where binding is measured at several concentrations of the labeled 
ligand at equilibrium to determine the affinity of the labeled ligand (Kd) and the 
number of receptor binding sites (Bmax); competition binding experiments, 
where binding of labeled ligand is measured in the presence of incrementing 
series of concentrations of a unlabeled compound at equilibrium to determine 
the affinity of unlabeled compound (Ki) (Hein et al. 2005, Hulme and Tre-
vethick 2010). Irrespective of the assay type, it is necessary to ensure that the 
labeled ligand is actually bound to the receptor. There are always two com-
ponents of ligand binding (also called total binding): a specific component that 
describes ligand binding to the receptor of interest, and a nonspecific com-
ponent that is affected by binding to other sites (Lazareno 2001). In addition to 
binding to the receptor, most ligands will bind to a greater or lesser extent to 
cell membranes, other proteins, plastic or glassware etc. (Flanagan 2016). Non-
specific binding is usually measured in the presence of an unlabeled ligand, 
which ideally only binds to the receptors of interest and therefore prevents 
binding of a labeled ligand to these specific sites. Specific binding cannot be 
directly measured and is rather calculated as a difference between total and non-
specific binding (Lazareno 2001).  
Development of the binding assay includes several overlapping, interactive 
and recursive stages, like initial choices of receptor source, labeled ligand and 
assay conditions, optimization, validation, application to novel ligands and 
quantitative analysis of the results (Hulme and Trevethick 2010). However, the 
availability of labeled ligands greatly limits the application of ligand binding 
assays (Hein et al. 2005). Therefore, development and characterization of novel 
fluorescent- or radioligands is an important part of GPCR research. 
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1.2.1. Radioligand binding assay 
Radioligand binding assay developed by Paton and Rang (Paton and Rang 
1965) has been one of the most widely used methods in GPCR research. It is 
also simple to perform – a preparation of the receptor is incubated together with 
a radiolabeled ligand. After that, the receptor-bound fraction of the radioligand 
will be quantified since the free radioligand will be separated by filtration. 
There are various radioisotopes, like 3H, 14C, 32P, 35S or 125I available that can be 
used for labeling ligands with minimal modifications of the chemical structure 
and therefore having no effect on the affinity of the ligand for the receptor. 
Many high affinity ligands are commercially available allowing to set-up an 
assay rather quickly. Among these, 3H- and 125I-labeled ligands are used most 
frequently (Hein et al. 2005). Iodinated ligands have high specific activity, short 
half-life (60 days) and high-energy γ-radiation making the assay very sensitive 
(Flanagan 2016). As a disadvantage, incorporating 125I into the structure of the 
ligand may change its affinity, particularly if it is a low molecular weight com-
pound (Hein et al. 2005). Therefore, iodine is more often used for labeling 
peptides. The key advantage of tritium is that it does not change the molecular 
structure of the ligand and therefore 3H is most frequently used to label smaller 
compounds, such as dopaminergic ligands. These ligands can be used for long 
time due to the long half-life (12.3 years) of 3H. Additionally, this isotope emits 
low-energy β-radiation that combined with low specific activity results in some-
what lower detection efficiency but is safer to use (Flanagan 2016). However, 
several 3H atoms could be incorporated into the structure of the ligand and this 
enables to detect affinities in subnanomolar range.  
While radioactivity-based assays are fast, sensitive, easy-to-use and repro-
ducible they also have some drawbacks: hazardous to human health, produce 
radioactive waste, require special laboratory conditions and licenses and are rather 
expensive (de Jong et al. 2005). One of the major disadvantage, limiting the use 
of radioligand binding assay for high-throughput screening, is the need to separate 
free ligand from its receptor-bound form. To overcome this problem, scintillation 
proximity assay (Hart and Greenwald 1979) can be used. It is a homogeneous 
assay in which only the radioligand binding to GPCR immobilized on the surface 
of beads can activate the scintillation beads that produce photons detectable with 
a scintillation counter. Thus, this assay type enables to carry out binding experi-
ments without washing or filtration steps (Zhang and Xie 2012). 
Usually, the radioligand binding assay is performed with homogenized tissue or 
cell membrane preparations or with intact cells. In this case, free radioligand can be 
separated from the receptor-bound fraction by filtration or centrifugation. With 
detergent-solubilized receptors more specialized approaches, for example gel 
filtration (Rinken et al. 1994), must be used. Binding assays may also be performed 
with cells attached to culture dishes or with tissue slices attached on slides. After 
incubation, free radioligand can be simply removed with the medium. This can 
improve automation of the assay but contravenes with the theoretical requirement 
that both the receptor and ligand should be freely diffusible (Flanagan 2016). 
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1.2.2. Fluorescent ligand binding assay 
Optical methods, like colorimetric, fluorescence or (chemo-/bio-)luminescence 
detection systems, have emerged as alternatives to radioactivity-based assays 
(de Jong et al. 2005). Among these, spectroscopic methods, for example assays 
based on color development, are not very sensitive and selective compared to 
fluorescence or luminescence measurements. An ideal assay for GPCR ligand 
screening should be easy-to-perform, sensitive, nonradioactive, robust, homo-
genous and easily adaptable to a microtiter plate for robotic automation (Zhang 
and Xie 2012). These criteria are met with fluorescence-based methods, which 
also enable monitoring of ligand binding in real time. During the last decades 
there has been a remarkable growth in the use of fluorescence in biochemistry 
due to fluorophores with enhanced brightness, greater photostability and 
improved physical properties like pH stability and water solubility (Hertzberg 
and Pope 2000). The choice of the fluorescent dye for labeling ligands is critical 
in assay development. For low molecular weight ligands, the size of the dye, 
use of a linker and its length as well as the position of the fluorophore are of 
major importance (de Jong et al. 2005). A bulky fluorophore may lead to signi-
ficant changes in binding properties, e.g. result in lower affinity. This is the 
major limiting factor in development of fluorescence-based assays. Therefore, 
the labeled ligand should always be considered as a novel compound that 
should be thoroughly characterized. 
Fluorescence measurements can provide information on a wide range of 
molecular processes, like the interaction of solvent molecules with fluoro-
phores, rotational diffusion of biomolecules, distances between sites of bio-
molecules, conformational changes, and binding interactions (Lakowicz 2006). 
As with any method, fluorescence-based techniques also have some limitations: 
fluorescence emission can be quenched or scattered and high background 
autofluorescence interferes with detection of specific fluorescent signal. The 
latter can be reduced by using dyes with high excitation wavelength. Higher 
sensitivity and precision can be achieved with long lifetime lanthanides (Eu, 
Tb), because the background signals tend to have shorter life-times (de Jong et 
al. 2005). Promising results have been also obtained with Förster resonance 
energy transfer (FRET) based methods, but this usually requires labeling of 
both the receptor and the ligand (Rinken et al. 2018). Another possibility is to 
determine the binding of fluorescent ligand to the GPCR by monitoring 
decrease in its lateral mobility. This can be measured with fluorescence corre-
lation spectroscopy, that detects fluctuations in fluorescence intensity upon 
diffusion of fluorescent ligand through a small detection volume (Briddon and 
Hill 2007). Additionally, receptor-bound fluorescent ligand also has less rota-
tional freedom when compared with the free ligand and this can be detected by 
fluorescence anisotropy (FA) that is commonly used in biochemical measure-
ments (Rinken et al. 2018). It is based on the phenomenon that upon excitation 
with polarized light, fluorophores whose dipole is parallel to the plane of 
polarized light will absorb and emit light. This will result in partially polarized 
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emission and the degree of polarization depends on the fluorophore’s freedom 
of movement within its lifetime (Lakowicz 2006). Thus, binding of low mole-
cular weight fluorescent ligand to a larger receptor causes an increase in FA that 
is calculated as follows: 
 
  =  ∥ ⟘∥ ⟘      (1) 
 
where ∥ and ⟘are the fluorescence intensities of the parallel and perpendicular 
components of the emitted light respectively. Denominator of the fraction 
( ∥ + 2 ⟘) corresponds to total fluorescence intensity (TFI) of the emitted light.  
One of the most critical steps in FA assay is labeling of the ligand – in addition 
to retaining high affinity, coupling of the fluorophore to the pharmacophore 
should be rigid enough so that the fluorophore cannot rotate freely upon fluore-
scent ligand binding to the GPCR. Moreover, properties of the fluorescent dye 
also have to meet the FA requirements. One important parameter to be con-
sidered is fluorophore’s lifetime – for low molecular weight ligands it should 
remain between 2 – 5 ns. Other important properties of the fluorescent dyes 
include high extinction coefficient, quantum yield, emission wavelength and 
stability as well as low bleaching and nonspecific binding (Rinken et al. 2018). 
These criteria are largely met by the fluorescent dyes Cy3B and Bodipy FL that 
are employed in current thesis. 
The homogeneous nature of FA assay makes it a so-called mix-and-measure 
type technique, which is often an advantage when it comes to assay automation 
and miniaturization for high-throughput applications. Additionally, high-quality 
data obtained from FA assay enables to determine the affinities of the fluore-
scent ligand and competitive ligands as well as kinetic parameters for labeled 
and unlabeled ligands. However, for good measurement window, the con-
centrations of the fluorescent ligand and the receptor need to be comparable to 
cause significant depletion of the labeled ligand as a result of the binding pro-
cess (Nosjean et al. 2006). Such receptor concentrations are not present in 
native tissues and therefore overexpression systems need to be used. 
 
 
1.3. Expression systems 
One of the important aspects of ligand binding assays is the source of receptors 
as the system where the interactions are studied in. If we want to study the 
effects of drugs designed for humans, then the best choice would be testing in 
human subjects. Historically, experiments were often performed on humans. 
For example, in 1805 Friedrich Serturner administered a dose of morphine, an 
alkaloid isolated from opium, to himself and his friends (Scheindlin 2001). All 
of them experienced symptoms of severe opium poisoning for several days. 
Unfortunately, research involving humans is littered with a history of scandals 
and unethical experimentation. Nowadays, experimenting on humans in strictly 
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regulated and is usually carried out only with promising drug candidates during 
clinical studies. More commonly various test animals, especially mammals are 
used in pharmacological studies. Mice are often preferred because of their small 
size, ease of breeding, and short generation time (Scheindlin 2001). Also, rats, 
guinea pigs, rabbits and dogs are used, depending on the tests performed. Expe-
riments could be performed on live animals, for example to test the toxicity of 
new drugs or to conduct behavioral experiments to investigate the effects of 
various compounds on central nervous system. More often pharmacology em-
ploys the use of isolated organs or tissues, which could also be used to perform 
ligand binding experiments on native receptors. However, most of the initial 
pharmacological screening is currently performed with various types of cells. 
Cells are a good model system providing a consistency and reproducibility of 
results that cannot always be achieved with the abovementioned options. Ligand 
binding experiments could be performed on live cells (intact cells) or on cell 
membrane homogenates.  
The low natural abundance of GPCRs limits the use of native tissues for 
ligand binding assays. To overcome this problem, various overexpression sys-
tems that enable the production of recombinant protein have been developed 
and successfully applied. This can be done by introducing foreign genetic mate-
rial into the chosen cell line. In the case of eukaryotic cells, the process is called 
transfection which can be further divided into two different types: transient and 
stable. Transient transfection is one of the most employed method for delivering 
genes inside the cell. With this method, foreign gene is expressed for a limited 
time and the gene is not incorporated into the cell’s genome (Kim and Eberwine 
2010). The mayor advantage of transient transfection is its quickness – it takes 
only a few days to go from a purified genetic material to the expressed protein 
(Andréll and Tate 2013). The drawback of this method is that it is difficult to 
achieve high transfection levels and invariable transfection efficiency. However, 
this is not a problem in some cases, for example in microscopy experiments 
where only transfected cells could be chosen for imaging. Contrarily, in stably 
transfected cells the foreign gene becomes part of the genome and therefore 
transgene expression is maintained even after replication (Kim and Eberwine 
2010). Although creation of high producing stable line takes months to develop, 
after successful establishment the expression of protein is fast, robust and 
usually with high yield (Nettleship et al. 2010).  
There are several different techniques available for introducing the protein 
encoding gene into a cell. These methods can be broadly classified into three 
groups: chemical, physical and biological. Some of the widely used chemical 
methods involve transfection reagents like cationic polymers, calcium 
phosphate and cationic lipids. Physical methods include electroporation and 
microinjection and biological approaches include the use of various viruses 
(Kim and Eberwine 2010). Ideally, DNA should be delivered with high effi-
ciency, low cell toxicity and minimal effects on normal physiology. Other 
important criteria include ease of use and reproducibility. However, each of the 
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abovementioned methods possess its own advantages and disadvantages and 
thus must be chosen according to certain purpose and cell type.  
One of the most critical steps of recombinant protein expression is the choice 
of cell line, which should be selected according to the final goal bearing in mind 
that for a certain application one system may be more suitable than another. The 
closest alternative to GPCR native environment can be achieved in mammalian 
cells and therefore this system is widely used for functional studies in cases 
where correct post-translational modifications and natural signal transduction 
components are necessary for ligand recognition and receptor signaling (Nettle-
ship et al. 2010). Correct N-glycosylation, post-translational machinery and 
molecular chaperones as well as a suitable lipid environment can be guaranteed 
while using mammalian cells (Andréll and Tate 2013). A lot of decisions need 
to be made while working with mammalian cell lines. First, a choice between 
immortalized cultured cell lines and primary cells must be made. For decades, 
cultured cell lines have played a critical role in scientific achievement, yet re-
searchers have become increasingly concerned about the clinical relevance of 
these cells. Therefore, more attention is turned to primary cells that have been 
isolated directly from human or animal tissue. These cells are physiologically 
more relevant and generally maintain the characteristics (function, morphology, 
protein expression) of the parent tissue (Pappas 2010). Unfortunately, this great 
advantage is accompanied by some drawbacks: protocols for isolating primary 
cells are more complex, they have a finite life span, the cells are very sensitive 
and need optimized culture conditions and careful handling, growing might be 
more time-consuming and expensive (Bury et al. 2014, Pappas 2010). For these 
reasons, primary cells have not yet replaced immortalized cell lines that have 
undergone mutations allowing continuous division, such as tumor cells. The 
cultured cells are easy to grow and obtain, relatively cheap and GPCRs can be 
stably expressed with rather high expression levels. A widely used example of 
mammalian cells is human embryonic kidney (HEK293) cell line. It was 
derived from primary kidney cells four decades ago by transformation with 
fragments of adenovirus type five DNA (Graham et al. 1977). Although 
HEK293 cells are isolated from kidney, it has been shown to possess charac-
teristic of neuronal cells and therefore this cell line is especially suitable for 
studying central nervous system receptors (Shaw et al. 2002). This cell line has 
many advantages, like quick reproduction, relatively easy maintenance, high 
efficiency of transfection and protein production, and reliable translation and 
processing of proteins (Thomas and Smart 2005). Furthermore, natural presence 
of mRNA for 28 GPCRs has been demonstrated in HEK293 cells, implying that 
corresponding signaling pathways are operational (Shaw et al. 2002). 
In addition to mammalian cells, wide variety of cell lines derived from lower 
organisms are also available. Among these, insect, yeast and bacteria are used 
more frequently, especially if an expression system without interfering GPCRs 
and G proteins is preferred. For structural studies, GPCRs have been expressed 
in bacteria and yeast, which provide high levels of protein, are easy to scale-up 
and inexpensive to grow. Prokaryotic nature of the bacteria is associated with 
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drawbacks of the system, such as inability to perform necessary post-transla-
tional modifications, lack of G proteins, problems with protein folding, and in 
some cases low expression levels or truncated forms of the receptor. Yeast cells 
are capable to perform post-translational modifications similar to more complex 
eukaryotic cells, but the N-glycosylation of mammalian membrane proteins is 
inefficient, and existence of cell wall may hinder recovery of non-secreted pro-
teins (Massotte 2003). Insect cells are often used to produce high amounts of 
GPCRs for crystallization studies, due to the easy and effective large-scale 
expression and eukaryotic protein processing capabilities. Researchers have 
found that it is easier to overexpress functional mammalian membrane protein 
in insect cells rather than in bacteria (Andréll and Tate 2013). Still, not all the 
post-translational modifications are similar to those of higher eukaryotes and 
special caution should be taken while working with glycoproteins (Kost et al. 
2005). Efforts have been made to overcome this problem by developing an 
insect cell line that has a more mammal-like glycosylation pattern (Aumiller et 
al. 2012).  
Insect cell expression system usually includes the use of invertebrate-spe-
cific viruses, called baculoviruses (BVs) and referred to as baculovirus expres-
sion vector system that is one of the most versatile eukaryotic expression sys-
tems available for protein production. The principal BV used for GPCR pro-
duction is Autographa californica multiple nucleopolyhedrovirus (AcMNPV) 
with Spodoptera frugiperda (Sf9) cells derived from the ovarian tissue of fall 
armyworm as the host (Nettleship et al. 2010). First, protein encoding cDNA is 
inserted into a plasmid transfer vector under a strong polyhedrin promoter. 
Polyhedrin is naturally produced at very high levels to protect the BV particles 
from the environment and is nonessential for viral propagation in cell culture 
and can therefore be replaced by gene of interest (Massotte 2003). Next, site-
specific transposition of the plasmid into a BV shuttle vector (bacmid) takes 
place (Luckow et al. 1993, Ciccarone et al. 1998). The bacmid is then pro-
pagated in Escherichia coli bacteria, purified and transfected into Sf9 cells to 
generate recombinant BVs. After that, the BV stock will be amplified to obtain 
a high-titer virus that can be used to infect cells for large-scale expression of the 
recombinant protein. One of the important steps in BV preparation is to deter-
mine the amount of infectious viral particles in high-titer virus prior protein 
production. This is necessary because one important infection parameter for 
protein expression is multiplicity of infection (MOI) that corresponds to the 
number of virus particles per cell. Optimal MOI should be established for each 
virus, medium, reactor and cell line to achieve the highest expression of active 
protein (Invitrogen Life Technologies 2013).  
BVs infect many different insect species but do not propagate in any non-
invertebrate hosts, including humans. The ease of use and low risk (Biosafety 
level 1) have been major factors in the widespread application of baculovirus-
insect cell expression system (Kost et al. 2006). BVs enter the cells via faci-
litated endocytosis or fusion, followed by uncoating and replication of viral 
DNA and production of recombinant GPCRs on the surface of Sf9 cells. During 
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the BV infection cycle virus particles start to bud from the Sf9 cell, taking a part 
of the host’s membrane, including membrane proteins with them. Thus, baculo-
virus-insect cell expression system represents a versatile tool for displaying re-
combinant GPCRs on the surface of Sf9 cells as well as on budded BV particles 
(Mäkelä and Oker-Blom 2008). These budded BVs are rod-shaped particles 
(approximately 200–400 nm in length and 40–50 nm in diameter) that could be 
separated from Sf9 cells by centrifugation and employed as a source of recep-
tors for ligand binding assays (Veiksina et al. 2014). Furthermore, the GPCRs 
displayed on the surface of budded BV particles are in their native conform-
ation, orientation and environment. Using these particles ensures that only fully 
matured and membrane-bound proteins are present in the assay. Still, it should 
be taken into consideration that the lipid composition of insect cells and mam-
malian cells differs, especially by the sterol content: mammalian cells contain 
predominantly cholesterol, while insect cells have ergosterol (Mäkelä and Oker-
Blom 2008).  
Even though BVs cannot replicate in mammalian cells, recombinant viruses 
containing mammalian cell-derived expression cassettes can function as gene 
delivering agents (Kost et al. 2006). This is called the BacMam system and it 
has many advantages such as high transduction rates, low cytotoxicity to host 
cells, expression level adjustment by amount of virus used, compatibility with 
various cell lines and ease of handling due to low biosafety level (PAPER II, 
Kost and Condreay 2002, Kost et al. 2006). 
Finally, ligand binding experiments can also be performed with solubilized 
and purified receptors. Usually, a recombinant receptor is expressed in one of 
the previously described cell lines and then purified for further experiments. A 
serious obstacle is the requirement to extract the receptors from their native en-
vironment in the plasma membrane, coupled with the inherent instability of 
GPCRs in the detergents required for their solubilization (Jamshad et al. 2015). 
After purification it is often necessary to reconstitute them into a lipid structure 
such as a liposome. Upon success, receptors could be studied in a controlled 
environment and detailed information about molecular mechanisms underlying 
ligand binding, receptor activation and downstream signaling could be obtained. 
Recently, considerable progress has been made to visualize GPCRs and their 
signaling complexes at the structural level. According to GPCR database, 50 
unique GPCR crystal structures are currently available and the number is in-
creasing exponentially. 
Dopamine receptors were the focus of this study, because these receptors are 
implicated in many neurological processes and abnormal signaling can lead to 
several neurological and psychiatric disorders. Our approach included develop-
ment of novel assay systems to characterize ligand binding to different subtypes 
of dopamine receptors in various sources of receptors. Experiments were carried 
out with native GPCRs (tissue homogenates) and with various recombinant 
protein expression systems (mammalian and insect cells, budded baculovirus 
particles). Several methods were implemented to study receptor-ligand inter-
actions with the emphasis on fluorescence-based assays. 
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2. AIMS OF THE STUDY 
General aim of this study was to find novel possibilities to study the properties 
of dopamine receptors. The thesis mostly focused on dopamine D1 receptors and 
implementing fluorescence-based methods to gain further insight about 
receptor-ligand interactions. The study design included several subtasks: 
 
 To investigate possible link between expression of endoplasmic reticulum 
transmembrane protein wolframin and dopamine D1-like receptor. 
 To determine involvement of dopaminergic receptors in behavioural effects 
caused by the peptide lunasin. 
 To validate the use of budded baculovirus particles as a source of receptors 
for radioligand binding assay. 
 To implement fluorescence anisotropy-based assay for studying ligand 
binding to dopamine receptors. 
 To characterize and quantify fluorescent ligand binding to dopamine 
receptors in live cells. 
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3. MATERIALS AND METHODS 
3.1. Reagents and cell lines 
Spodoptera frugiperda (Sf9) cells were obtained from Invitrogen Life Techno-
logies and maintained as a suspension culture in a serum-free insect cell 
medium EX-CELL 420 (Sigma-Aldrich) without antibiotics at 27 °C in a non-
humidified incubator. Human embryonic kidney cells (HEK293) stably ex-
pressing human wild-type dopamine D1, D2L or D3 receptors were generated by 
Dr. Reet Reinart-Okugbeni as described in Reinart-Okugbeni et al. 2012. The 
cells were grown as an adherent monolayer on Petri dishes (Thermo Scientific, 
BioLite) in Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose 
supplemented with 10% fetal bovine serum (both from Sigma-Aldrich),  
100 U/ml penicillin, 100 μg/ml streptomycin (NAXO, Smart Media) and 400 
μg/ml geneticin (PAA Laboratories) at 37 °C in a humidified incubator with 5% 
CO2. Density and viability of HEK293 and Sf9 cells were determined with the 
addition of 0.2% trypan blue (BioTop) using an Automated Cell Counter 
TC20™ (Bio-Rad Laboratories). 
NaCl, KCl, KOH, KH2PO4, ethylendiaminetetraacetic acid (EDTA), MgCl2, 
CaCl2, NaOH, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS), HCl, dimethyl 
sulfoxide (DMSO), dithiothreitol (DTT) were from Applichem. Na-HEPES was 
obtained from Amresco, Pluronic F-127 was from Sigma-Aldrich and bovine serum 
albumin (BSA) was purchased from PAA Laboratories. Complete EDTA-Free 
Protease Inhibitor Cocktail was used according to the manufacturer’s description 
(Roche Applied Science). Dopaminergic ligands apomorphine, dopamine and (+)-







chromene-5,6-diol (A68930) and spiperone were from Tocris. R(-)-pro-
pylnorapomorphine (NPA) was obtained from Research Biochemicals Inter-
national and 2-methoxy-10,11-dihydroxy-N-propylnorapomorphine (MNPA) 
was from PharmaSynth. Radioligands [3H]SCH23390 (specific activity 84.3 
Ci/mmol or  81.9 Ci/mmol), [3H]Raclopride (74.0 Ci/mmol or 70.5 Ci/mmol), 
[3H]WAY10063 (74.0 Ci/mmol) and [3H]NMS (84.1 Ci/mmol) were from 
PerkinElmer. Total protein concentrations of the samples were determined with 
Bradford protein assay kit (Bio-Rad Laboratories) according to the manu-
facturer’s protocol. The fluorescent ligand BodipyFL-SKF83566 (CellAura 
# 200773) specific for dopamine D1 receptors was developed in the University 
of Nottingham, UK and was kindly provided by Professor Stephen Hill.  
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3.2. Receptor preparations 
3.2.1. Mice brain hippocampal tissue 
Wild-type (wt) C57BL/6 (Scanbur) and wolframin (Wfs1) knockout mice were 
housed under standard laboratory conditions as described in PAPER III. Wfs1-
deficient mice do not suffer from gene inactivation and studies with these mice 
have been approved by the Estonian National Board of Animal Experiments. 
Obtaining mice tissue was performed after rapid execution and no manipula-
tions with the animals occurred before. For radioligand binding experiments, 
the hippocampi were dissected on ice immediately after decapitation, frozen in 
liquid nitrogen and stored at -90 °C. All these procedures were carried out by 
Dr. Triin Tekko and her colleagues at the Institute of Biomedicine and Trans-
lational Medicine, University of Tartu.  
Hippocampal membranes were prepared as described in Tõnissaar et al. 
2008 with some modifications. Briefly, hippocampal tissue of wt or Wfs1 
knockout mouse was homogenized in 1 ml of ice cold homogenization buffer 
(HB: 50 mM Tris-HCl, pH = 7.4) with a Bandelin Sonopuls sonicator for 3 ×  
10 s cycles. Membrane suspension was then collected by centrifugation at  
30 000 × g for 20 min at 4 °C (Sigma 3K30, SIGMA Laborzentrifugen). After 
that, supernatant was discarded and the obtained pellet was rehomogenized in  
1 ml of HB. This washing procedure was repeated three times and the final 
homogenization of membrane suspension was done in 50 ww/v of the in-
cubation buffer (IB: 50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, 5 mM MgCl2, 
1 mM EDTA, pH = 7.4). The final suspensions (20 mg tissue/ml) were stored at 
-90 °C until further use. 
 
 
3.2.2. Sf9 cells and budded baculovirus particles  
Recombinant viruses of dopamine D1 and D3 receptors were used in this work 
and constructed based on a Bac-to-Bac® Baculovirus Expression System (In-
vitrogen Life Technologies). The pcDNA3.1(+) expression vectors (Invitrogen 
Life Technologies) encoding human wild-type dopamine receptors D1 or D3 
were purchased from the cDNA Resource Center. Both genes were cloned into 
pFastBac1 vectors under the strong polyhedrin promoter to achieve high-level 
protein expression. The obtained constructs were transformed into competent 
DH10Bac cells (Invitrogen Life Technologies) to generate recombinant bac-
mids. Purified and PCR-verified bacmids were then transfected into Sf9 cells 
with a transfection reagent ExGen 500 (Fermentas) according to the manu-
facturer’s protocol. These low-titer viral stocks were collected and used to 
infect Sf9 cells (1.5×107 cells) to produce passage P1 BVs, which were further 
amplified to gain high-titer BVs that could be used for protein production.  
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3.2.2.1. Determination of baculovirus titers 
BV titers were estimated with a viable cell size-based titration method (PAPER 
II). First, Sf9 were seeded to a 24-well cell culture plates (Thermo Scientific, 
BioLite) at a density of 2×105 cells/well in 250 μl of EX-CELL 420. After 30–
60 minutes of incubation at 27 °C cells were infected with 250 μl of 3-fold 
serial dilutions of the harvested virus. Each virus dilution was pipetted to the 
plate in duplicates and the Sf9 cells were incubated with the virus for 24 hours. 
After that, cells along with the supernatant (500 μl) were transferred to a vial 
containing 9.5 ml of ISOTON II Diluent (Beckman Coulter) and average cell 
diameter was measured with Cell and Particle Counter (Z2 Series Coulter 
Counter, Beckman Coulter). To determine the concentration of infectious viral 
particles (ivp) a sigmoidal dose-response curve was fitted to a data obtained by 
plotting average cell diameter versus virus dilution factor. The virus titer was 
calculated by assuming that a cell can be infected by only one BV particle 
(Janakiraman et al. 2006, Laasfeld et al. 2017) with the following equation: 
 Virus concentration (ivp/ml)  =  ×  ×    (2) 
 
where N – number of cells in single well at the time of infection (here 200 000); 
EC50 – virus dilution at which the average cell diameter has changed 50%; V – 
the solution volume of a single well (here 0.5 ml).  
 
 
3.2.2.2. Production of receptors 
For the generation of membrane preparations and budded baculoviruses, Sf9 
cells were infected with a high-titer recombinant BV at a density of 2.0 ×  
106 cells/ml at multiplicity of infection MOI = 5. In case of Sf9 membrane pre-
parations, cells were grown for 48 h until the viability of the cells had dropped 
to approximately 90%. After that, cells were harvested and centrifuged at 1000 
× g for 5 min at room temperature. The pellet was stored at -90 °C until further 
preparation of membranes (described in 3.2.3).   
To produce BV particles, cells were collected after the viability had de-
creased below 50% (approximately 72 hours) by centrifugation at 1000 × g for 
10 minutes. After that, the supernatant was collected and centrifuged again for 
45 minutes at 48 000 × g at 4 ºC. The pellets were first washed and then 
resuspended in assay buffer (AB: 11 mM Na-HEPES, 0.1% Pluronic F-127,  
0.1 mg/ml BSA, 1 mM MgCl2, 1 mM CaCl2, 5 mM KCl, 135 mM NaCl and 
Protease Inhibitor Cocktail, pH = 7.4). Final volume of the AB was chosen so, 
that the BV preparation was concentrated 27 times in comparison of the initial 
cell suspension volume. The samples were then aliquoted and stored at -90 ºC 
until used for experiments. 
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3.2.3. HEK293 cells stably expressing dopamine receptors 
Membrane preparations were produced from the HEK293 cells stably ex-
pressing either dopamine D1, D2L or D3 receptors. HEK293 cells at approxi-
mately 95% confluency were harvested in Dulbecco’s Phosphate-Buffered 
Saline (DPBS) without Ca2+ and Mg2+ (NAXO, Smart Media) and centrifuged 
at 1000 × g for 5 minutes at room temperature. The pelleted cells were stored at 
-90 °C until preparation of membrane suspensions.  
The cell membranes were prepared as described previously (Reinart-Okug-
beni et al. 2012). Briefly, Sf9 or HEK293 cells (about 1.5 × 108 cells/tube) were 
melted on ice, washed with 20 ml of ice-cold HB and collected by centri-
fugation at 800 × g for 5 min at 4 °C. In case of Sf9 cells, protease inhibitor 
cocktail (Roche Applied Science) was added to the HB according to manu-
facturer’s instructions. Next, the cells were resuspended in 20 ml of HB and 
homogenized with a homogenizer (Coleparmer Labgen 125) for at least 30 s. 
After that, membranes were collected by centrifugation at 30 000 × g for 20 min 
at 4 °C. The latter washing/centrifugation step was repeated once more, and the 
obtained membrane pellets were finally homogenized in IB so that a con-
centration of c ≈ 107 cells/ml would be achieved. Obtained Sf9 and HEK293 
membrane preparations were stored in 1 ml aliquots at -90 °C until further use. 
 
 
3.3. Ligand binding assays 
3.3.1. Radioligand binding assay 
All the radioligand binding experiments were performed on round bottom 96-
well plates (Greiner) and the reactions were carried out in a final volume of  
250 μl per well. Assay buffer was IB supplemented with 1 mM of DTT just 
before the experiment. In the following subsections, preparation of samples and 
concentrations of reagents is described in detail for each particular membrane 
sample. However, all the procedures performed after the samples had already 
been carried to the assay plate remained the same. The plates with samples were 
incubated for 60 min (in case of saturation binding experiments) or for 90 min 
(competition binding experiments) at 25 °C. The reactions were stopped by 
separating free radioligand with rapid filtration through thick GF/B glass fiber 
filtermats (Perkin Elmer) using FilterMate Harvester (model D961962, 
PerkinElmer). Filters were then washed 5 times with an ice-cold washing buffer 
(WB: 20 mM K-phosphate, 100 mM NaCl, pH = 7.4), after which the filters 
were dried in a microwave oven at 800 W for 2 minutes. Solid scintillant 
MeltiLexTM B/HS was then impregnated into the filter using a MeltiLexTM Heat-
sealer and filter-bound radioactivity was counted with a Wallac MicroBeta 
TriLux 1450 LSC Luminescence Counter (all from PerkinElmer). Total con-
centrations of the radioligand dilutions were determined in vials with 3 ml of 
liquid scintillation cocktail OptiPhase HiSafe (PerkinElmer).  
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3.3.1.1. Mice hippocampal membranes 
In saturation binding experiments the hippocampal membranes of six mice from 
either wt or Wfs1 knockout group were pooled and used at a concentration of 
20 mg tissue/ml. The membranes (3 mg tissue/well) were incubated with in-
creasing concentrations of radioligand [3H]SCH23390 in the absence (total 
binding) or in the presence (nonspecific binding) of 10 μM (+)-butaclamol. Data 
are obtained from three independent experiments performed in duplicates. 
To estimate the number of binding sites of D1-like receptors in individual wt 
and Wfs1 knockout mice, specific binding of 4 nM [3H]SCH23390 was 
determined. For that, tissue concentration of 6.7 mg/ml (1 mg tissue/well) was 
used. All these experiments were carried out at least in duplicates for 22 wild-
type and 24 Wfs1-deficient mice. 
 
 
3.3.1.2. Sf9 and HEK293 cell membrane preparations and  
budded baculovirus particles 
In saturation binding experiments, 150 μl of receptor preparations were added to 
a solution containing 50 μl of different concentrations of [3H]SCH23390 (final 
0.01–9 nM) and 50 μl of IB (for total binding) or 1 μM (+)-butaclamol (final 
concentration, for nonspecific binding). All 4 to 6 repetitive experiments were 
performed in duplicates.  
For competition binding experiments, the receptor preparations were in-
cubated with different serial dilutions of unlabeled ligands and with a fixed 
concentration of radioligand (near it’s KD value). The competition binding 
experiments (n = 2–3) were performed in triplicates. Inhibition constant (Ki) 
values were calculated from competition binding curves according to the 
Cheng-Prusoff equation (Cheng and Prusoff 1973) that enables to calculate the 
affinity for one-site non-cooperative binding model. 
 
 
3.3.2. Fluorescence anisotropy assay 
Fluorescence anisotropy experiments were performed with dopamine D1 recep-
tor selective fluorescent ligand BodipyFL-SKF83566. Concentration of the 
ligand was estimated by measuring absorbance at 507 nm using an UV-1800 
spectrophotometer (Shimadzu). An assumption that extinction coefficient did 
not change when fluorophore was attached to the ligand was made in order to 
calculate the concentration of the ligand. After that, aliquoted stocks of the 
fluorescent ligand were stored at -20 °C in DMSO and further diluted in assay 
buffer before an experiment. 
All the experiments were performed with black 96-well half area, flat bottom 
polystyrene NBS microtiter plates (Corning, Product No. 3993) as these have 
been found to give low background fluorescence as well as low adsorption of 
ligands onto the plastic surface (Veiksina et al. 2010). FA measurements were 
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carried out in a final volume of 100 μl/well at 27 °C using a PHERAstar plate 
reader (BMG LABTECH) with polarized excitation and dual emission, which 
allows to simultaneously record intensities that are parallel ( ∥) and perpendi-
cular ( ) to the plane of excitation light. For BodipyFL-SKF83566 excitation at 
485 nm (filter bandwidth 10 nm) and emission at 520 nm (filter bandwidth  
10 nm) was used. Sensitivities of these two emission channels (G-factor) were 
corrected with erythrosine B as a standard (Thompson et al. 2002). Addi-
tionally, all the experiments included blank sample wells, where no fluore-
scence ligand was added, but same amount of BV was used as in other assay 
points.  
In saturation binding assays two different concentrations of a fluorescent 
ligand were used in the presence of 8 µM (+)-butaclamol for nonspecific 
binding or in absence of (+)-butaclamol in case of total binding. Finally, serial 
dilutions of BV particles expressing dopamine D1 receptors were added to all 
the wells to start the binding reaction. Altogether, three independent saturation 
binding experiments were carried out in duplicates. 
To determine the kinetic properties ligand binding was initiated by addition 
of BV preparation containing D1 receptors to a given concentration of fluore-
scent ligand (with or without 1 μM (+)-butaclamol) and the reaction was 
monitored in time. Dissociation was initiated after completion of the association 
reaction by addition of (+)-butaclamol (final c = 1 μM) or IB. Because the as-
sociation and dissociation kinetics were fast no replicates were used and 
experiments were rather repeated several times (n = 5). 
In competition binding experiments, fixed concentrations of the fluorescent 
ligand and BV particles were incubated with serial dilutions of various un-
labeled ligands. Measurements were performed in duplicates and at least three 
independent experiments were carried out with each ligand. 
Blank corrected fluorescence anisotropy was calculated from fluorescence 
emission intensities measured parallel and perpendicular to the plane of ex-
citation light as described in detail in Veiksina et al. 2014. Software Aparecium 
2.0 developed in our laboratory by Tõnis Laasfeld and available at 
http://www.gpcr.ut.ee/software.html was used for kinetic data acquisition and 
transformation. The affinity parameters (KD of BodipyFL-SKF83566 and Ki 




3.3.3. Fluorescent ligand binding to intact cells 
These experiments were performed with a novel fluorescent ligand NAPS-
Cy3B (Figure 2) synthesized by Mihkel Ilisson at the Chair of Organic Che-
mistry, University of Tartu. The ligand is a conjugate of the fluorophore Cy3B 
and D2-type receptors’ selective antagonist N-(p-aminophenethyl)-spiperone 
(NAPS). An amide formation reaction with Cy3B NHS-ester (GE Healthcare) 
and NAPS (Carbosynth Ltd) was carried out to couple the ligand with the 
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fluorescent dye. Desired compound was purified by HPLC, and its identity and 
purity were further confirmed by HPLC-MS (reaction yield 5.1 %).  
HEK293 cells stably expressing dopamine receptors were grown as de-
scribed previously in chapter 3.1. Trypsin-EDTA (0.005/0.002%, NAXO, Smart 
Media) was used for cell passaging to gain homogenous distribution of the cells 
on the Petri dish and to minimize the formation of cell aggregates. At the day of 
the experiment cells were seeded to a black 96-well Ibidi μ-plate at a density of 
20 000 cells/well in 150 μl of DMEM. Cells were incubated at 37 °C for 5 h and 
after that the cell culture medium was replaced with the same volume of DPBS 




Figure 2. Chemical structure of the fluorescent ligand NAPS-Cy3B that is selective for 
D2-like receptors. The ligand is a conjugate of N-(p-aminophenethyl)-spiperone (black) 
and the fluorophore Cy3B (red).  
 
 
The concentration of the NAPS-Cy3B solution was determined spectrophoto-
metrically by measuring absorbance at 574 nm with the assumption that 
extinction coefficient of the fluorophore remains unchanged when it is coupled 
to the ligand. Aliquoted stocks of the fluorescent ligand were stored at -20 °C in 
DMSO and further diluted in DPBS before an experiment. Final concentration 
of NAPS-Cy3B in the experiments was 1 nM and nonspecific binding was mea-
sured in the presence of 1 μM (+)-butaclamol. For the competition experiments, 
serial dilutions of unlabeled ligands (dopamine or (+)-butaclamol) were added 
to wells containing HEK293 cells and 1 nM NAPS-Cy3b. Bright-field and 
fluorescence microscopy images were obtained with Cytation 5 Imaging Multi-
Mode Reader (BioTek), which has high-content imaging capabilities. Images 
were obtained using a LUCPLFLN 20× objective lens (WD 6.6, NA 0.45) 
(Olympus). For fluorescent images the excitation was performed with a 523 nm 
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LED cube together with the RFP filter having excitation at 531 nm (bandwidth 
40 nm) and emission at 593 nm (bandwidth 40 nm). The average fluorescence 
intensity of membrane pixels was estimated using the membrane detection 
algorithm incorporated into software Aparecium 2.0 (http://www.gpcr.ut.ee/ 
software.html). 
All the data were analyzed using GraphPad Prism 5.0 (GraphPad Software) 
and are presented as mean ± S.E.M. if not stated otherwise. Statistically signi-
ficant differences were determined by Student’s t-test, where P < 0.05 was 
taken as the criterion of significance.  
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4. RESULTS AND DISCUSSION 
4.1. Influence of wolframin expression to dopamine D1-like 
receptor levels in mouse hippocampal membranes 
Wolframin is a glycoprotein located in the membrane of endoplasmic reticulum 
and loss of its function causes a rare disease called Wolfram syndrome (Hof-
mann et al. 2003). The symptoms of this autosomal recessive neurodegenerative 
disorder include diabetes insipidus, diabetes mellitus, optic atrophy and deaf-
ness (Rigoli et al. 2011). Additionally, neurological complications and psychiat-
ric disorders are frequently occurring among patients with Wolfram syndrome 
(Swift et al. 1990). The mechanisms causing these latter symptoms are largely 
unknown and therefore it is necessary to further investigate the reasons of 
abnormal brain functioning.  
The radioligand binding assay is a sensitive assay, which provides quanti-
tative about expression levels of GPCRs and affinities of different ligands for 
these receptors (Flanagan 2016). Here we have used this method to evaluate the 
receptor expression levels in hippocampal tissue. First, the expression patterns 
of wolframin in the brain could be investigated. It is known that Wfs1 is 
expressed in several rodent brain regions associated with control of behaviour 
and emotions (Takeda et al. 2001, Luuk et al. 2008). The behavioural responses 
to environmental stimuli are mediated via dopaminergic system and therefore 
we hypothesized that wolframin could affect the functioning of this pathway. 
Immunohistochemical study indicated that the expression pattern of wolframin 
is largely overlapping with that of D1-like receptors, especially with D1 subtype 
(PAPER III). To gain further knowledge about the influence of wolframin to 
the levels of dopamine D1-like receptors, we used Wfs1 gene knockout mice 
(Luuk et al. 2009) together with wild-type mice as a control group. The number 
of binding sites of dopamine receptors in the mouse hippocampus were assayed 
with [3H]SCH23390, which is a selective ligand for D1-like receptors. As this 
radioligand has high affinity for D1 (Zhou et al. 1990) as well as for D5 recep-
tors (Sunahara et al. 1991, Ricci and Amenta 1994) that are both expressed in 
hippocampus and have quite similar roles (Sarinana et al. 2014), the following 
conclusions are valid for both D1-like receptors. 
Mouse brain and consequently the hippocampus are rather small (~25 mg) 
and thus the hippocampal tissue of a single mouse is not sufficient for obtaining 
the radioligand binding curve. Therefore, several mice hippocampi were pooled 
for these experiments. The radioligand [3H]SCH23390 bound to hippocampal 
membranes with high affinity, having KD values of 0.31 ± 0.06 nM and 0.48 ± 
0.08 nM for wt and Wfs1 gene knockout mice, respectively (Figure 3A). The 
number of binding sites was higher for Wfs1-deficient mice (Bmax = 4.0 ±  
1.3 fmol/mg tissue) than in the case of wild-type mice (Bmax = 1.5 ±  
0.1 fmol/mg tissue) (Figure 3A). To check the number of D1-like receptor 
specific binding sites in individual mice, 4 nM concentration of [3H]SCH23390 
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was used. At this concentration approximately 90% of available receptors are 
labeled and therefore adequate information about the number of total binding 
sites could be obtained. The number of detected binding sites for Wfs1 knock-
out mice, 2.7 ± 0.6 fmol/mg tissue, was significantly higher (P < 0.05) than 
corresponding value of 1.1 ± 0.4 fmol/mg tissue for wt mice (Figure 3B). The 
number of binding sites determined in these latter experiments was lower, 
because all of the receptors could not be detected. However, both of these 
experiments demonstrate increased levels of D1-like receptors in hippocampi of 
Wfs1-deficient mice.  
 
A     B 
 
 
Figure 3. Comparison of specific binding of radioligand [3H]SCH23390 to hippo-
campal membranes of wt and Wfs1 knockout mice. A – Saturation binding curve of 
[3H]SCH23390 binding to pooled samples of six wt or Wfs1 knockout mice. The 
membrane suspensions (3 mg/well) were incubated with different concentrations of 
[3H]SCH23390 for 60 min and bound radioactivity was measured as described in 
Materials and Methods. Data presented as mean ± S.E.M. from a representative experi-
ment (n = 3) performed in duplicates. B – The level of [3H]SCH23390 binding sites of 
individual wt (n = 22) and Wfs1 (n = 24) knockout mice determined in hippocampal 
membrane suspensions (1 mg/ml) incubated with 4 nM radioligand. Data presented as 
mean ± S.E.M. of all the mice tested. *P < 0.05 vs wt mice. 
 
 
Previous experiments with Wfs1-deficient mice have shown that various points 
in dopaminergic signalling cascade are altered compared to wt mice. For 
example, functional studies indicated that wolframin is necessary for normal 
dopamine secretion in the striatum (Matto et al. 2011) and for dopamine trans-
porter expression in midbrain (Visnapuu et al. 2013). Additionally, Wfs1-defi-
cient mice demonstrate abnormal responses to dopamine agonists (Visnapuu et 
al. 2013, Luuk et al. 2009). All these results indicate impaired functioning of 
dopaminergic system in the animal model of Wolfram syndrome. Our study 
suggests that alterations in dopaminergic signalling are caused, at least in part, 
by the upregulation of D1-like dopamine receptor expression in Wfs1-deficient 
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mice (PAPER III). This could in turn influence the activity of ligands and 
should be tested in functional assays. On one hand, higher dopamine receptor 
expression levels might enhance signalling in Wfs1 gene knockout mice. On the 
other hand, higher number of binding sites might be a compensatory mechanism 
for maintaining normal dopaminergic signal transduction due to lower levels of 
dopamine in the synaptic cleft. Similar effect has been seen in Parkinson’s 
disease model, when 6-hydroxydopamine is injected to animals to induce dege-
neration of dopamine neurons (Ungerstedt 1968), resulting in increased expres-
sion levels and activity of dopamine D2-type receptors (Terasmaa et al. 2000).  
Clearly, the role of wolframin in dopaminergic signalling needs further in-
vestigation, especially concerning the postsynaptic signalling pathways. One of 
the possibilities is to generate primary cultures from hippocampal tissue of 
Wfs1-deficient and wt mice, which could later be used as a source of receptors 
in functional assays. A widely used method is GTPγS binding assay. However, 
this is typically suitable for GPCRs coupled to Gi/o proteins, like dopamine D2-
type receptors, and would not be the method of choice for D1-type receptors. 
Another option would be to monitor a change in the concentration of second 
messenger molecule cAMP. This could be carried out with a Förster resonance 
energy transfer (FRET)-based biosensor system that allows real-time detection 
of changes in cellular cAMP concentrations (Mazina et al. 2012, PAPER II). 
Unfortunately, functional assays were outside the focus and time-frame of this 
study but could be carried out in the future.   
 
 
4.2. Determining the effect of lunasin to  
dopamine receptors 
Lunasin is a 43-amino acid peptide isolated from soybeans (Odani et al. 1987, 
Galvez and de Lumen 1999). The peptide has an unusually high proportion of 
aspartic acid residues and nine out of ten of these residues are located in the 
carboxyl terminus forming a polyaspartyl sequence. The structure also contains 
a cell adhesion motif RGD (Odani et al. 1987). The biological activity of luna-
sin was first discovered in 1999 when A. Galvez together with his colleagues 
discovered that the peptide binds to chromatin and arrests cell division. Since 
then, many health-promoting properties of lunasin have been described. For 
example, its cancer-preventing activity (de Lumen 2005, Hernandez-Ledesma et 
al. 2009a), anti-inflammatory and antioxidant effects (Hernandez-Ledesma et 
al. 2009b, de Mejia and Dia 2009) and cholesterol-lowering properties (Galvez 
2012, Gu et al. 2017). It is also known that upon oral administration lunasin can 
enter the target tissues in an intact and bioactive conformation and is able to 
cross the blood-brain barrier (Hsieh et al. 2010). This is presumably due to 
naturally occurring protease inhibitors in soy and other lunasin containing 
seeds, that protect lunasin from digestion making it bioavailable. This in turn 
generates a possibility that lunasin may also affect nervous system. Thus, we 
carried out experiments to study the effect of lunasin on the behavioural 
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responses in mice (PAPER I). It was seen that administration of lunasin 
induced motionlessness and catalepsy. Catalepsy is also a symptom of Parkin-
son’s disease and mostly caused by dopamine receptors antagonism. Therefore, 
the influence of lunasin to behaviour caused by known dopaminergic drugs was 
determined. It was seen that lunasin reduces hyperlocomotion caused by admi-
nistration of amphetamine as well as apomorphine-induced climbing. The ob-
tained results indicate that the effects of lunasin to behaviour occur, at least in 
part, via dopamine receptors and therefore pharmacological properties of luna-
sin on dopamine receptors were evaluated. 
In these experiments membrane preparations of HEK293 cells stably ex-
pressing either dopamine D1 or D2 receptor were used. Radioligand binding 
studies demonstrated modest affinity of lunasin for dopamine D1 receptor with 
Ki = 60 ± 15 µM (Figure 4). Dopamine was used as a control (Figure 4) and 
the determined affinity (Ki = 36 ± 7 µM) was in good agreement with the pre-
viously published data from our workgroup (Reinart-Okugbeni et al. 2012). 
However, no dose-dependent decrease in binding of radioligand [3H]Raclopride 
upon increasing concentration of lunasin was observed for dopamine D2 re-
ceptors (data not shown). 
 
 
Figure 4. Displacement of [3H]SCH23390 by dopamine or lunasin at dopamine D1 
receptors in HEK293 cell membranes. Serial dilutions of either dopamine or lunasin 
were incubated with radioligand (c = 1 nM) and membrane preparations for 90 min at 
25 °C. Results were obtained from two independent experiments performed in dupli-
cates. Data on the graph are from a representative experiment. 
 
 
To further investigate lunasin’s effect on dopamine receptors we wanted to test 
the biological activity of the peptide in FRET-based biosensor assay that allows 
real-time detection of changes in cellular cAMP levels (PAPER II). It was 
observed that lunasin inhibited the cAMP formation initiated by agonist apo-
morphine (10 nM) in HEK293 cells expressing dopamine D1 receptor. The 
apparent pIC50 value was 6.1 ± 0.3 (n = 5) for lunasin and 7.61 ± 0.03 (n = 5) 
 42  
for D1-specific antagonist SCH39166 used as a control. Neither agonistic nor 
antagonistic properties of lunasin were seen in cells expressing D2 receptors. 
The data obtained from radioligand binding studies and cAMP assay indicate 
that D1 receptor, rather than D2, may play an essential role in mediating luna-
sin’s effects. In addition to dopaminergic system, other non-identified mecha-
nisms may be involved in the behavioural effects of lunasin.  
 
 
4.3. Implementing budded baculoviruses as a source of 
dopamine receptors for radioligand binding assay 
It has been proved that baculovirus particles that have budded from Sf9 cells 
have active receptors on their surface. For example, it has been shown that BVs 
are a good source of melanocortin 4 receptors (Veiksina et al. 2014) and sero-
tonin 5-HT1A receptors (Tõntson et al. 2014) in fluorescence anisotropy-based 
assay. Generally, this expression systems results in correct folding of proteins, 
high expression levels and post-translational modifications similar to mam-
malian proteins. The ease of use and low risk of biohazard (Biosafety level 1) 
are also major advantages of this expression system (Kost et al. 2006). In 
PAPER II we have optimized and described all the steps required to generate, 
harvest and titrate BVs in order to obtain high-quality receptor preparation. This 
enables different laboratories to achieve comparable results, which is of utmost 
importance in terms of reproducibility.  
Since dopamine receptors are in the focus of drug discovery and several 
fluorescent ligands have been synthesized for D1- and D2-like receptors (Mons-
ma et al. 1989, Bakthavachalam et al. 1991, Tabor et al. 2017) then we decided 
to implement fluorescence anisotropy-based assay to characterize ligand 
binding to these receptors. For that, we focused on dopamine D1 receptor and 
produced a high-titer BV that could be used to infect a large number of insect 
cells. It was seen that MOI = 5 should be optimal to achieve sufficient dopa-
mine D1 receptor expression. Once the budded baculoviruses were obtained we 
decided to characterize these in a radioligand binding assay. The assay is 
usually carried out with tissue or cell membrane preparations, which allow rapid 
separation of the free radioligand from the receptor-bound fraction. However, 
these sources of receptor cannot be considered a homogenous system, rather a 
mixture of lipoparticles with very different shapes and sizes with the additional 
uncertainty about the orientation of receptors in these particles (Bailey et al. 
2009). Alternatively, receptors could be solubilized and purified followed by 
reconstitution into artificial lipid vesicles (Haga et al. 1985). This method 
enables to achieve a homogeneous receptor preparation but requires high 
amounts of protein and is labor-intensive. As a compromise, BVs could be used 
as a source of receptor, since the size of BV particles is uniform, and the orien-
tation of receptor remains the same as it was in Sf9 cell membrane. The suitabi-
lity of BVs for the radioligand binding assay was tested in PAPER IV, where 
the obtained results were also compared with the receptors in “classical” 
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membrane preparations (HEK293 and Sf9 cells). Total protein concentrations of 
all these preparations were determined with the Bradford assay kit and remained 
in the range on 0.4–0.7 mg/ml. The samples were further diluted for the radio-
ligand binding experiments to achieve comparable level of binding and to avoid 
problems with ligand depletion.  
First, saturation binding experiments were carried out to evaluate the  
number of binding sites and the affinity of the radioligand. The binding of 
[3H]SCH23390 was with high affinity and saturable with the nonspecific 
binding remaining below 25% of the level of total binding for all the receptor 
preparations studied. The KD was similar for Sf9 cells and BV particles con-
taining D1 receptors, being 1.7 ± 0.2 nM and 1.8 ± 0.2 nM respectively. These 
values are in good agreement with the results obtained previously for D1 recep-
tors expressed in Sf9 cells (He et al. 2003, Uustare et al. 2006), but somewhat 
higher than the KD of 0.5 ± 0.1 nM determined in HEK293 cell membranes. The 
number of binding sites again coincided for Sf9 cells and BV particles, having 
Bmax values of 9.2 ± 0.5 pmol/mg and 9.8 ± 1.7 pmol/mg protein respectively, 
giving additional evidence that the receptors in these two preparations have 
similar properties. The specific binding determined in HEK293 membranes was 
slightly lower with the Bmax = 6.3 ± 0.4 pmol/mg. Even though it should be 
taken into account that receptors expressed in insect cells have a different 
environment than in mammalian cells, the obtained results demonstrate that 
BVs could be used as a membrane preparation in radioligand binding assay. 
High expression level of dopamine D1 receptors could be achieved with BVs 
and this makes these an attractive choice for the pharmacological screening of 
ligands.  
Competition binding experiments were carried out to compare the general 
pharmacological profile of these three different membrane preparations expres-
sing dopamine D1 receptors. Altogether, five known dopaminergic agonists and 
four antagonists were tested and all of the ligands resulted a concentration-
dependent inhibition of [3H]SCH23390 binding to D1 receptors in all of the 
studied preparations. The pIC50 values (Table 1) obtained from the competition 
binding curves and corresponding Ki values were in good agreement with each 
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Table 1. pIC50 values of dopamine D1 receptor agonists and antagonists determined 
in competition binding experiments performed with Sf9 or HEK293 membrane 
preparations or with BVs. Serial dilutions of unlabeled compounds together with 
radioligand [3H]SCH23390 were incubated with different receptor preparations for 90 
min at 25 °C. Results were obtained from at least two independent experiments per-




HEK293 Sf9 BV 
Agonists    
Apomorphine 5.89 ± 0.22 6.16 ± 0.18 5.99 ± 0.20 
Dopamine 4.29 ± 0.24 4.95 ± 0.10 5.04 ± 0.10 
MNPA 5.20 ± 0.10 5.61 ± 0.10 5.31 ± 0.12 
SKF81297 7.04 ± 0.14 6.83 ± 0.10 6.86 ± 0.10 
A68930 7.25 ± 0.10 8.00 ± 0.23 7.61 ± 0.22 
Antagonists    
LE300 8.00 ± 0.24 7.98 ± 0.13 8.21 ± 0.16 
(+)-butaclamol 8.84 ± 0.10 8.74 ± 0.10 8.90 ± 0.35 
SCH23390 8.74 ± 0.19 8.36 ± 0.18 8.82 ± 0.10 
Spiperone 5.69 ± 0.10 6.06 ± 0.11 6.26 ± 0.10 
 
 
These experiments indicated that budded BVs are a suitable source of dopamine 
D1 receptors. However, baculoviruses have been widely implemented to study 
other GPCRs and therefore we decided to test a selection of receptors in radio-
ligand binding studies. In addition to dopamine D1 receptors we have obtained 
similar results with D3 receptors (with radioligand [3H]Raclopride) (data not 
shown), serotonin 5-HT1A receptors (with [3H]WAY100635), M1 and M2 
muscarinic acetylcholine receptors (with [3H]NMS) (Figure 5). The pharmaco-
logical properties of these receptors remained unchanged and we are confident 
that the same approach can be applied for other GPCRs as well. Another impor-
tant aspect is that BVs provide a homogenous system, which allows to use con-
siderably longer incubation times, if necessary, to reach an equilibrium, without 
risk of aggregation or precipitation (PAPER IV). All the data demonstrate that 
budded baculoviruses are a suitable source of membrane receptors for the 
radioligand binding studies. 
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4.4. Fluorescence anisotropy-based assay for studying 
ligand binding to dopamine receptors 
Radioligand binding assay is a good choice for determining the binding affinity 
of the ligands as well as the number of binding sites. However, it is a so-called 
endpoint-based method and therefore gives limited information about the 
binding process. For example, it is more difficult to accurately measure reaction 
kinetics, due to the necessity of sampling each time point separately. Fluore-
scence-based assays, like fluorescence anisotropy, have emerged as promising 
methods that allow on-line monitoring of binding reactions without the need to 
take individual samples in time. One limiting factor of the FA assay is that it 
requires high receptor concentration due to its ratiometric nature, which means 
that FA signal depends on the concentration of both the free and the receptor-
bound fluorescent ligands. Therefore, the concentrations of the receptor and the 
fluorescent ligand need to be comparable. As the previous results demonstrated, 
high expression levels of D1 receptor can be achieved with BVs, we further tried 
to implement these BVs for FA assay. 
Binding of fluorescent ligands can lead to change in FA as well as in total 
fluorescence intensity and both of these signals could be used to monitor ligand 
binding. Among the available fluorescent ligands, we have found that 
BodipyFL-SKF83566 is the most promising candidate for the characterization 
of ligand binding to D1 receptors (PAPER V). Addition of D1 receptor BVs to 
BodipyFL-SKF83566 caused a concentration-dependent increase in TFI. How-
 
Figure 5. Competition binding experiments performed on budded baculovirus par-
ticles containing either serotonin 5-HT1A (), M1 (♦) or M2 (▲) muscarinic ace-
tylcholine receptors. Serial dilutions of unlabeled ligands 8-OH-DPAT (in case of 5-
HT1A), NMS (M1) and AFDX-384 (M2) were incubated with radioligand (1.6 nM 
[3H]WAY10063 for 5-HT1A and 0.6–0.7 nM [3H]NMS for muscarinic acetylcholine 
receptors) along with BV preparation for 90 minutes at 25 °C. The data is presented as 
mean ± S.E.M. from a representative experiment performed in triplicates. 
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ever, this increase did not depend on receptor activity as there were no signifi-
cant differences in the TFI measured for total and nonspecific binding (deter-
mined in the presence of 1 µM (+)-butaclamol). It can be suggested that this 
increase in TFI could be caused by autofluorescence of BVs as similar increase 
was also detected in the absence of the BodipyFL-SKF83566. 
However, it was observed that addition of BV preparation containing D1 
receptors to the fluorescent ligand caused a time-dependent increase in FA 
values (span ≈ 0.1) that reached a plateau within 3 minutes (Figure 6). Approxi-
mately half of this FA change could be attributed to the specific binding to the 
dopamine D1 receptors as blocking the receptors with 1 μM (+)-butaclamol also 
resulted in an increase in FA compared to the signal obtained for the free 
fluorescent ligand without BVs. After the association of BodipyFL-SKF83566 
to D1 receptors was completed (10 min after starting the reaction) dissociation 
reaction was started by addition of 1 μM (+)-butaclamol. Decrease in FA, 
corresponding to the dissociation of fluorescent ligand from the D1 receptors, 
was observed, and it reached the level of nonspecific binding within about 7 
minutes (Figure 6). These results indicate that the change in FA could be attri-
buted to binding of BodipyFL-SKF83566 to dopamine D1 receptors and it can 
be monitored in real-time. The fluorescent ligand binds to dopamine D1 recep-
tors reversibly and the fast association and dissociation kinetics (half-lives 




Figure 6. Time course of FA change caused by binding of BodipyFL-SKF83566 to 
dopamine D1 receptors in budded baculovirus particles. The reaction was initiated 
by addition of D1 receptors to 4.6 nM BodipyFL-SKF83566 in the absence (,●) and 
presence (×) of 1 μM (+)-butaclamol. After 10 min (indicated with an arrow) the mea-
surement was paused and dissociation was initiated by addition of 1 μM (+)-butaclamol 
(●) or an equivalent volume of assay buffer (). Data are from a representative set of 
five independent experiments performed.  
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Another important aspect of the fluorescent ligand is the affinity, which was mea-
sured with two separate methods (PAPER V). First, the ability of BodipyFL-
SKF83566 to compete with radioligand [3H]SCH23390 in membranes of 
HEK293 cells stably expressing D1 receptors was tested. BodipyFL-SKF83566 
caused a concentration-dependent inhibition of [3H]SCH23390 binding which 
could be characterized with a pIC50 = 7.79 ± 0.01 and a corresponding Ki = 6.0 ± 
1.8 nM. To directly determine the affinity of BodipyFL-SKF83566 in the FA 
assay, total and nonspecific binding (with 8 μM (+)-butaclamol) were measured at 
two different concentrations of the fluorescent ligand (2.3 nM and 18.4 nM) by 
varying the amount of D1 receptor BVs. The binding parameters were obtained by 
fitting the data to equations adapted for FA assay (Veiksina et al. 2014) and the 
KD value of 5.19 ± 0.15 nM was obtained. This is in very good agreement with 
the affinity determined in radioligand binding assay and coincides with the 
affinity previously determined for similarly modified SKF83566 (Baktha-
vachalam et al. 1991). The nanomolar range affinity is sufficient for using 
BodipyFL-SKF83566 as a reporter ligand in the FA assay. 
As binding of BodipyFL-SKF83566 to dopamine D1 receptors can be direct-
ly monitored we used it to characterize the binding properties of various dopa-
minergic ligands. For that, ligands with up to four orders of magnitude diffe-
rence in affinities were chosen. All of these competition binding experiments 
yielded one-site binding curves with the pIC50 and corresponding Ki values 
close to the previously reported affinities (Table 2). Similar dose-response 
curves were obtained when these unlabeled ligands were also tested in radio-
ligand binding experiments with D1 receptor BVs. The pIC50 and Ki values 
determined from these experiments coincided with the results from the FA 
assay (Table 2). A linear correlation between pKi values was obtained from the 
affinities determined for the same ligands with the two aforementioned methods 
(Figure 7). The coefficient of determination (R2) was 0.96 and the slope did not 
significantly differ from unity nor y-intercept from zero. These results suggest 
that BodipyFL-SKF83566 is a suitable reporter ligand for FA assay and the 
assay system described here is readily applicable for high-throughput screening 
of novel dopaminergic ligands. 
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Table 2. Binding affinities of dopaminergic ligands for dopamine D1 receptors in 
baculovirus particles determined in radioligand binding assay in competition with 
[3H]SCH23390 or in fluorescence anisotropy assay with BodipyFL-SKF83566. The 
values are expressed as mean ± S.E.M. of three independent experiments performed in 
duplicates (FA assay) or two measurements performed in triplicates (radioligand 
binding assay). 
 Radioligand binding Fluorescence anisotropy 
 pIC50  Kia, nM  pIC50 Kib, nM 
Agonists:   
Dopamine 5.04 ± 0.10 6770 ± 110  5.09 ± 0.10 5300 ± 880 
Apomorphine 5.99 ± 0.20 840 ± 360  5.44 ± 0.10 1710 ± 150 
A68930 7.61 ± 0.22 20.0 ± 9.3  7.24 ± 0.10 38.5 ± 5.5 
SKF81297 6.86 ± 0.10 99 ± 11  6.70 ± 0.10 119 ± 21 
SKF38393 5.99 ± 0.10 665.9 ± 2.5  5.20 ± 0.10 1850 ± 370 
NPA 5.59 ± 0.10 1663 ± 46  5.65 ± 0.10 1210 ± 110 
Antagonists:      
SCH39166 8.52 ± 0.14 2.05 ± 0.63  8.17 ± 0.10 4.8 ± 1.6 
(+)-butaclamol 8.90 ± 0.35 1.23 ± 0.84  8.62 ± 0.27 1.70 ± 0.76 
LE300 8.21 ± 0.16 4.8 ± 1.6  8.24 ± 0.19 3.7 ± 1.7 
Spiperone 6.26 ± 0.10 390 ± 31  5.85 ± 0.10 622 ± 86 
SCH23390 8.82 ± 0.10 1.08 ± 0.21  8.06 ± 0.12 3.61 ± 0.60 
a Ki were calculated from displacement curves according to the Cheng-Prusoff equation 
(Cheng and Prusoff 1973). 
b Ki were calculated by fitting the data to a set of equations implemented previously for 
fluorescence anisotropy competition experiments (Veiksina et al. 2014). 
 
 
Figure 7. Comparison of apparent affinities of dopaminergic ligands in fluorescence 
anisotropy assay with apparent affinities measured in radioligand binding assay. 
BodipyFL-SKF83566 was used as a reporter ligand in FA assay and [3H]SCH23390 
was applied in the radioligand binding assay. Results (mean ±S.E.M.) were obtained 
from three independent experiments performed in duplicates (FA assay) or at least two 
measurements performed in triplicates (radioligand binding assay) after 90 min of 
incubation. R² = 0.96 
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As demonstrated above, fluorescent ligand BodipyFL-SKF83566 binding to D1 
receptors could be monitored on-line (Figure 6). It has been demonstrated 
earlier that kinetic parameters of the unlabeled ligand can be calculated from 
kinetic data of competition binding curves (Rinken et al. 2018). Unfortunately, 
kinetics of the studied dopaminergic ligands (Table 2) were too fast for this 
instrumental setup to reliably estimate kinetic constants for these ligands. How-
ever, monitoring the change of apparent pIC50 values in time during the com-
petition experiments, temporary over- or underestimation of pIC50 could be 
observed (PAPER V). For example, there was a temporary overestimation of 
the affinity of dopamine, which indicates that this ligand is faster than 
BodipyFL-SKF83566, and the underestimation of SCH23390’s affinity indi-
cates that the competitor has slower binding kinetics than the fluorescent ligand 
(PAPER V). This information gives general estimation about the competitor’s 
kinetic properties even though exact rate constants could not be determined. Of 
course, real kinetic constants can be obtained for all these ligands, but it re-
quires special equipment with an automatic dispensing and shaking system as 
well as smaller number of samples. As this would give information about the 
binding mechanism of a particular ligand, but is not usable for general screening 
studies, it remained outside the scope of the current study. Our assay set-up with 
96-well plates and conventional plate spectrofluorimeter equipped with a 
polarizer (Veiksina et al. 2015) does not allow to follow the fast ligand binding 
kinetics, where half-lives are shorter than a minute.  
Usually the overall cost of the assay depends mostly on the amount of recep-
tor and ligands needed. In the FA assay, 96-well half-area plates are used, 
which allow considerably smaller sample volumes per well than feasible in 
radioligand binding experiments were filtration and washing steps are required. 
This is an important advantage when high molecular weight ligands with low 
affinity are tested. For example, radioligand displacement experiments with 
lunasin resulted in 50% inhibition of radioligand [3H]SCH23390 binding upon 
highest lunasin concentration (32 μM) used (Figure 4). Since we already 
showed that FA assay with BodipyFL-SKF83566 is a suitable method for the 
characterization of ligand binding to dopamine D1 receptors, we also used the 
method to validate the results of lunasin. The smaller assay volume enabled to 
use up to 100 μM concentrations of lunasin in competition binding experiments 
and therefore it was possible to more accurately determine the lower plateau of 
the lunasin’s binding curve. Figure 8 demonstrates the concentration-depen-
dence of FA for lunasin and dopamine (used as a control) and the obtained 
pIC50 values were 4.81 ± 0.05 for lunasin and 4.93 ± 0.02 for DA. Consequent 
Ki values were calculated as described in Veiksina et al. 2014 and resulted in  
Ki = 12.2 ± 2.5 μM and Ki = 5.66 ± 0.58 μM for lunasin and DA, respectively. 
These results are in good agreement with the estimated affinity of lunasin 
measured in PAPER I. 
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Figure 8. Displacing fluorescent ligand BodipyFL-SKF83566 by dopamine or 
lunasin at dopamine D1 receptors in budded baculovirus particles. Serial dilutions 
of either dopamine or lunasin were incubated together with BodipyFL-SKF83566 (c = 
2.3 nM) and BV particles at 27 °C. Fluorescence anisotropy was measured 90 min after 
start of the reaction. Results were obtained from two independent experiments per-
formed in duplicates. Data on graph are from a single representative experiment. 
 
 
4.5. Visualization of ligand binding to  
dopamine receptor in live cells 
In addition to dopamine D1 receptors we also tried to develop assay systems to 
study D2-like receptors. As there were no commercially available ligands for 
these receptors, we decided to find a suitable candidate by ourselves. Fluore-
scent ligand NAPS-Cy3B appears to be a promising reporter ligand because 
NAPS has been shown to retain its affinity even after coupling to a fluorescent 
dye (Monsma et al. 1989) and fluorophore Cy3B is known to be a suitable 
choice for receptor studies (Veiksina et al. 2010).  
First, NAPS-Cy3B was tested in a FA assay with BVs expressing D3 
receptors. Addition of D3 receptor BVs to the fluorescent ligand did not cause a 
significant change in TFI, while clear receptor-specific change in FA could be 
detected. However, even after the optimization of measurement conditions (like 
concentrations of the fluorescent ligand and the receptor, incubation time) the 
signal window remained below 0.03, which is too low to reliably measure 
ligand binding to D3 receptors. We then determined the affinity of NAPS-Cy3B 
in a competition assay with radioligand [3H]Raclopride in HEK293 cells stably 
expressing D3 receptors and the corresponding results were pIC50 = 8.95 ± 0.28 
and Ki = 0.71 ± 0.38 nM. Hence, the affinity of this fluorescent ligand should be 
sufficient for FA assay and is not responsible for the small specific signal. This 
could be caused by the properties of the fluorescent ligand – if the fluorophore 
is able to rotate even after the fluorescent ligand has bound to the receptor then 
the increase in FA upon ligand binding could be negligible.  
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High affinity of NAPS-Cy3B to dopamine D3 receptors determined in a 
radioligand competition assay indicates tight binding of the fluorescent ligand 
to these receptors and therefore it should be also possible to characterize NAPS-
Cy3B binding to D3 receptors in live cells. To verify this, we performed fluore-
scence microscopy experiments with live HEK293 cells stably expressing 
dopamine D3 receptors. The cells were incubated with NAPS-Cy3B in the 
absence (total binding) and in the presence of 1 μM (+)-butaclamol (nonspecific 
binding). There was a clear difference in binding patterns of total (Figure 9A) 
and nonspecific binding (Figure 9B) – in the first case, accumulation of NAPS-
Cy3B into the membrane could be detected, whereas no clear membrane 
labeling could be seen for nonspecific binding. We also performed experiments 
with HEK293 cells without any stable transfection and saw no significant 
binding of NAPS-Cy3B to cell membranes. The data indicate that NAPS-Cy3B 
binds specifically to dopamine D3 receptors expressed in HEK293 cells. 
 
 
   
 
Figure 9. Fluorescence microscopy images of 1 nM fluorescent ligand NAPS-Cy3B 
binding to HEK293 cells stably expressing D3 receptors. Total binding (A) was 
determined in the absence and nonspecific binding (B) was obtained in the presence of 
1 μM (+)-butaclamol after 90 minutes of incubation. The number of cells per well was 
25000. Scale bar corresponds to 50 μm. 
 
 
Since the obtained results indicated that NAPS-Cy3B can be successfully used 
in fluorescence microscopy experiments, we further tried to implement this 
technique in competition binding experiments. A clear concentration-dependent 
decrease in fluorescence intensity could be seen in experiments with the un-
labeled antagonist (+)-butaclamol (Figure 10). Higher concentrations of  
(+)-butaclamol resulted in lower fluorescence intensity while at lower con-
centrations the unlabeled ligand could not compete with NAPS-Cy3B for 
binding to dopamine D3 receptors. To use this method for screening of novel 
ligands, quantitative information needs to be acquired from the fluorescent 
images. Simple analysis, such as calculating the average intensity of the fluore-
scence images, gives poor results. Higher receptor-ligand complex concentra-
tion does give rise to the average intensity. However, differences in confluence 
A                B 
 52  
also change the average intensity of the image to a large extent and the exact 
number of cells in each image frame is practically impossible to control. There-
fore, an approach that takes into account only the fluorescence intensity of 
membrane pixels is preferred. Here, an algorithm developed by Tõnis Laasfeld 
as a “Membrane Tools” module of Aparecium 2.0 software was used for quanti-
fication. As a result, the relative amount of fluorescent ligand NAPS-Cy3B 
bound to the D3 receptors in HEK293 cell membranes could be quantified. This 
enables us to obtain dose-response curves for unlabeled dopaminergic ligands 
(Figure 11) and to determine the corresponding pIC50 values, which were 6.63 
± 0.28 for dopamine and 7.67 ± 0.17 for (+)-butaclamol. Additionally, no 
specific binding and its changes could be detected when wt HEK293 cells were 




Figure 10. Inhibition of fluorescent ligand NAPS-Cy3B binding by (+)-butaclamol. 
HEK293 cells (20000 cells/well) stably expressing dopamine D3 receptors were 
incubated with 1 nM NAPS-Cy3B and given concentrations of (+)-butaclamol for 90 
minutes. Bright field (left) and fluorescence (right) images were taken after 90 minutes 
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The fluorescence microscopy assays performed with live mammalian cells that 
are more similar to native environment of GPCRs than BV particles can provide 
additional data about dopaminergic ligand binding process. NAPS-Cy3B has a 
high affinity to D2-like receptors and spectral properties suitable for following 
processes in live cells. Unfortunately, its antagonistic properties make it im-
possible to characterize agonist-dependent effects like desensitization and endo-
cytosis. Thus, future aim would be to obtain a fluorescent agonist which could 
provide additional information about dopaminergic receptors. When employing 
high-end fluorescent microscopes, these processes could be even detected at a 




Figure 11. Competition binding curves of NAPS-Cy3B obtained from fluorescence 
microscopy experiments. Measurements were performed with either wt HEK293 cells 
() or HEK293 cells stably expressing D3 receptors (,). HEK293 cells (20000 cells/ 
well) were incubated with 1 nM NAPS-Cy3B and serial dilutions of either dopamine 
() or (+)-butaclamol (). The average fluorescence intensity of membrane pixels was 
estimated using the membrane detection algorithm incorporated into software Apare-
cium 2.0. 
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5. CONCLUSIONS 
Dopamine is an important neurotransmitter that mediates its functions through 
five different types of G protein-coupled receptors on the cellular plasma mem-
brane. Dysfunction of dopaminergic signalling is connected with several 
neurological and psychiatric disorders, like Parkinson’s disease, schizophrenia, 
Tourette’s syndrome, bipolar disorder, depression, hyperprolactinemia and 
attention deficit hyperactivity disorder. Therefore, acquiring further information 
about the signal transduction process mediated by dopamine receptors is 
essential.  
This thesis focuses on the development of novel assay systems to characte-
rize ligand binding to different subtypes of dopamine receptors. Experiments 
were carried out with native G protein-coupled receptors (tissue homogenates) 
and with various recombinant protein expression systems (mammalian and in-
sect cells, budded baculovirus particles). Additionally, several methods were 
implemented to study receptor-ligand interactions with the emphasis on fluore-
scence-based methods. 
Hippocampal membranes of wild-type and wolframin knock-out mice were 
tested in radioligand binding experiments to investigate possible link between 
the expression of wolframin and dopamine D1-like receptors. We have deter-
mined by [3H]SCH23390 binding that membranes of wolframin knock-out mice 
have higher number of dopamine D1-like receptors than the membranes of wild-
type mice. This upregulation of D1-like receptors may be connected with 
physiological abnormalities of Wolfram syndrome. 
We have studied the binding properties of lunasin, a bioactive peptide iso-
lated from soybeans, to dopaminergic receptors. Radioligand binding assay as 
well as fluorescence anisotropy-based assay demonstrated micromolar range 
affinity of the peptide to D1 receptors, while no effect to D2 receptors even at 
submillimolar concentrations was observed. 
We have shown that budded baculovirus particles can be used as a source of 
receptors for radioligand binding experiments. Obtained ligand binding para-
meters for D1 receptors in baculovirus particles were in good agreement with 
the results of “classical” membrane preparations (HEK293 and Sf9 cells). Same 
approach can also be applied for other receptors, as we have obtained similar 
results with D3 receptors, serotonin 5-HT1A receptors, M1 and M2 muscarinic 
acetylcholine receptors.  
The fluorescent ligand BodipyFL-SKF83566 is suitable for the characte-
rization of ligand binding to D1 receptors in baculovirus particles. This assay 
system enables to measure ligand binding in real time, so that more information 
about ligand binding kinetics is received. Obtained binding parameters were in 
good correlation with the parameters measured in radioligand binding assay. 
Homogeneous nature of the fluorescence anisotropy assay makes it readily 
applicable for high-throughput screening of novel dopaminergic drugs. 
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For D2-like receptors, a new high-affinity fluorescent ligand NAPS-Cy3B 
was synthesized. Even though it was not a good reporter ligand for fluorescence 
anisotropy-based assay, due to its modest signal window, it can be used in 
fluorescence microscopy experiments with live cells stably expressing D3 recep-
tors. In these experiments a clear concentration-dependent decrease in NAPS-
Cy3B binding was observed upon increasing concentrations of unlabeled anta-
gonist (+)-butaclamol. To reliably quantify binding of NAPS-Cy3B to D3 
receptors we have developed an algorithm that takes into account only the 
fluorescence intensity of membrane pixels. As a result, affinity of the compe-
titor could be estimated. An advantage of this assay system is that it enables to 
study ligand binding to dopaminergic receptors in live mammalian cells, which 
is very similar to the native environment of GPCRs. 
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7. SUMMARY IN ESTONIAN 
Dopamiini retseptoritele ligandi sidumise uurimist 
võimaldavate katsesüsteemide arendamine 
Dopamiin on organismis oluline virgatsaine, mis vahendab närvisignaali üle-
kannet organismis seostudes raku membaanis paiknevatele G-valguga seotud 
retseptorite perekonda kuuluvatele dopamiini retseptoritele. Häired dopamiiner-
gilises signaaliülekandes on seotud mitmete neuroloogiliste ja psühhiaatriliste 
haigustega, nagu näiteks Parkinsoni tõbi, skisofreenia, Tourette’i sündroom, 
bipolaarne häire, depressioon, hüperprolaktineemia ning tähelepanupuudulikku-
sega hüperaktiivsus. Seetõttu on dopamiini retseptorite signaaliülekande põh-
jalikum uurimine jätkuvalt päevakorral. 
Käesolev doktoritöö keskendub uudsete katsesüsteemide arendamisele, mis 
võimaldavad uurida ligandide seostumist erinevatele dopamiini retseptorite ala-
tüüpidele. Eksperimente viidi läbi nii natiivsete retseptoritega (homogeniseeri-
tud koed), kui ka erinevate rekombinantse valgu ekspressioonisüsteemidega 
(imetaja- ja putukarakud, pungunud bakuloviiruste osakesed). Retseptorite ja 
ligandide vaheliste interaktsioonide iseloomustamiseks rakendati nii klassikalist 
radioligandi sidumist kui ka mitmeid fluorestsentsil põhinevaid meetodeid. 
Metsik-tüüpi ning wolframiini geeni puudulikkusega hiirte hipokampustest 
valmistatud membraanpreparaate võrreldi radioligandi sidumiskatsetes, ees-
märgiga uurida võimalikku seost wolframiini ekspressiooni ja dopamiini D1-
tüüpi retseptorite vahel. Radioligandi [3H]SCH23390 seostumiskatsed näitasid, 
et wolframiini-puudulikel hiirtel on rohkem dopamiini D1-tüüpi retseptoreid kui 
tavalistel hiirtel. Kõrgem D1-tüüpi retseptorite ekspressioonitase võib olla 
otseselt seotud Wolframi sündroomiga.  
Antud töö käigus uuriti ka lunasiini, sojaubadest eraldatud peptiidi, sidumis-
omadusi dopamiini retseptoritele. Nii radioligandi sidumiskatsete kui ka 
fluorestsentsanisotroopia eksperimentide tulemusena nähti, et lunasiin seostub 
D1 retseptoritele mõõduka, mikromolaarses suurusjärgus afiinsusega. Seevastu 
lunasiini seostumist D2 retseptorile ei täheldatud. 
Töö käigus tõestati, et pungunud bakuloviiruse osakesi on võimalik kasutada 
D1 retseptorite allikana radioligandi sidumiskatsete läbiviimiseks. Testitud 
ligandide seostumisparameetrid langesid hästi kokku tavapärastest membraan-
preparaatidest (HEK293 ja Sf9 rakud) saadud tulemustega. Samasugust lähe-
nemist saab kasutada ka teiste G-valguga seotud retseptorite jaoks, sest radio-
ligandi katseid pungunud bakuloviirustega on sooritatud ka dopamiini D3, sero-
toniini 5-HT1A ja muskariinsete M1 ning M2 atsetüülkoliini retseptoritega. 
Fluorestsentsligand BodipyFL-SKF83566 osutus hästi sobivaks fluorestsent-
sanisotroopia katsete läbiviimisel D1 retseptoreid sisaldavate bakuloviirustega. 
Loodud katsesüsteem võimaldab jälgida ligandi sidumist reaalajas, iseloomus-
tades seega ka paremini protsessi kineetikat. Ligandide jaoks määratud seostu-
misparameetrid olid heas kooskõlas radioligandi sidumiskatsetes saadud 
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tulemustega. Antud katsesüsteemi ülesehitus omab potentsiaali dopamiiner-
giliste ravimikandidaatide kiirsõeluuringute läbiviimisel. 
Lisaks D1 retseptoritele, sooviti välja töötada ka fluorestsanisotroopial põhi-
nev katsesüsteem D2-tüüpi retseptorite uurimiseks. Selleks sünteesiti uus, kõrge 
afiinsusega antagonist NAPS-Cy3B. Tagasihoidlik signaaliaken ei võimaldanud 
antud fluorestsentsligandi usaldusväärselt rakendada fluorestsentsanisotroopia 
katsetes. Küll aga sobis NAPS-Cy3B hästi fluorestsentsmikroskoopia katsete 
läbiviimiseks. See võimaldab uurida ligandi sidumist D3 retseptoritele otse 
elusatel imetajarakkudel. Konkureeriva antagonisti (+)-butaklamooli kontsent-
ratsioonist sõltuv NAPS-Cy3B sidumine rakkudele näitas fluorestsentsligandi 
spetsiifilist seostumist D3 retseptoritele. Seostumise kvantifitseerimiseks loodud 
algoritm võimaldab arvesse võtta vaid membraanipikslite fluorestsentsinten-
siivsust. Antud katsesüsteemiga saab hinnata erinevate märgistamata ühendite 
afiinsust D3 retseptorile elusates rakkudes.  
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